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ABSTRACT
Generating MR image contrast from exogenous contrast media though chemical
exchange saturation transfer (CEST) offers several exciting new possibilities, such as
multicolored imaging, the interleaving of pre- and post-contrast images, and the potential
to perform ratiometric metabolic imaging. The major limitation of the deployment of CEST
imaging is the comparatively high detection limits of exogenous agents and particularly at
the low B1 power levels required to meet SAR requirements. The large chemical shifts
afforded by paramagnetic (paraCEST) agents permit more rapid exchange kinetics and
therefore potentially more effective contrast agents. Despite comparatively large chemical
shifts, many Ln3+ DOTA-tetraamide (DOTAM) chelates traditionally investigated as
CEST agents are predicted to have exchange kinetics that are considerably faster than
optimal at very low B1 powers. This work explores two methodologies for slowing water
exchange kinetics in Ln3+ DOTAM chelates and improving CEST imaging: structural
manipulation and encapsulation. In the first method, rigid Ln3+ NB-DOTAM chelates with
hydrophobic amide substituents was thoroughly studied using NMR spectroscopy
techniques in order to assess their ability to produce CEST contrast at low B1 power levels.
NMR techniques utilized included 1H NMR, variable temperature, COSY, and CEST
experiments. The phenyl amide substituent in the pseudo-axial position afforded chelates
with considerably slow water proton exchange rates and appreciably more CEST contrast
than isomeric chelates with the amide substituent in the pseudo-equatorial position. The
second method involved characterizing a vesicle system to be used for encapsulating a Ln3+
DOTAM chelate. The vesicles prepared were analyzed using the following NMR
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techniques: 1H NMR, T1, shift reagent, and CEST experiments. The vesicle system chosen
for study did not afford slow water exchange kinetics to enhance CEST contrast. A second
vesicle system was attempted but the vesicle synthesis was difficult, parameters studied
were not optimized, and the second system did not exhibit slow water exchange with the
limited amount of experiments run and data collected.
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CHAPTER 1. INTRODUCTION OF MEDICAL IMAGING AND
MAGNETIC RESONANCE
1.1.

The 123s of Medical Imaging

X-ray (1895)
When the effects of X-rays were first observed by William Crookes and Johann Hittorf
while working with Crookes tubes in the 1880s, the scientists noticed that film plates that
were kept near the tubes appeared fogged and had shadow artifacts despite the film plates
being wrapped in paper and protected from light. The observed effect was not investigated
and similar observations were made by many other scientists over the following years,
including Ivan Pulyui, Fernando Sanford, Philipp Lenard, and Nikola Tesla. However, in
1895, Wilhelm Röntgen stumbled across the X-ray phenomenon while working with
Crookes tubes and began studying the invisible rays methodically, calling them “X”
radiation due to the type of radiation being unknown. He published the first medical X-ray
of his wife’s hand (Figure 1.1.1) shortly after and the name “X-ray” stuck with the
technique.1

Figure 1.1.1. The first human X-ray performed.1 Wilhem Röntgen’s wife’s wedding ring is visible in the
image.

In this type of medical imaging2, short X-ray pulses with varying photon energy levels
are used to probe soft tissue in the body. The X-rays interact with the tissue of the body
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through two mechanisms. When the photons of the X-rays interact with an atom, the energy
of the photon ejects an electron. The photon can either use all of its energy to eject the
electron, in which case there are no scattering photons as a result of the interaction, or the
photon does not use up all of its energy and the energy left over scatters the photon in a
different direction with less energy, which can then interact with other atoms or can pass
through the tissue to the detector or leave the body in any direction. The former process is
known as the photoelectric effect and is the main source of contrast for this technique,
while the latter is known as Compton scattering and is the main source of noise in
radiographs. In both cases, the ejected electron is free to move around and ionize
neighboring atoms, creating free radicals which can damage DNA and wreak havoc inside
the patient’s body. 3-6
As the X-ray passes through the body, the photons interact with atoms and the energy
of the photons decreases as they are absorbed. When these photons are absorbed and are
no longer able to penetrate through tissue, they are not able to reach the detector and fewer
photons are detected in the shadow of the structure absorbing the photons. Since higher
energy photons are able to move more readily through tissue without being absorbed, the
X-rays used need to be higher in energy (hard X-rays) as opposed to lower in energy (soft
X-rays). In the body, most tissue is made up of C, H, O, and N atoms. These atoms absorb
lower energy photons and although the Compton scattering that occurs will show the
presence of tissue, the tissue types are indiscernible. However, since calcium is present in
high amounts in bones and teeth, this technique provides excellent contrast for the skeletal
system.
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Calcium has a high atomic number which allows it to efficiently absorb higher energy
X-ray photons without having any leftover scattering of the photons. This means that when
the high energy photons come in contact with calcium in the bones and teeth, the photons
are absorbed via the photoelectric effect and contrast is generated, while the photons that
don’t interact with the calcium will pass through the body and hit the detector without
interacting with many other atoms. This allows X-rays to be used to identify the pathology
of the skeletal system and cavities in the teeth. X-rays can also be implemented to probe
lungs and the abdomen by relying on the fact that trapped gases within these symptoms
appear clear on images due to their low absorption of X-rays in comparison with body
tissue. Thus, X-rays are utilized to diagnose lung diseases like pneumonia, lung cancer,
and pulmonary edema and to identify intestine obstructions. The contrast in the abdomen
can be increased with the administration of radiocontrast agents, which contain iodine or
barium, which are both higher atomic number elements and therefore absorb the high
energy photons well. These radiocontrast agents are given intravenously in the case of
iodine, or orally in the case of barium.
While this technique is incredibly useful in probing systems that are difficult to view,
X-rays are classified as a carcinogen, and prolonged, repeated exposure to the radiation
used in the technique can lead to an increase in cancer occurrence and developmental
problems in areas that are exposed.7-10 As a result, strict protective measurements are in
place for those collecting the X-rays as well as the patients, with most medical
professionals not giving X-rays unless it is medically necessary and the benefit of having
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the image outweighs the risk of exposing the patient to radiation, no matter how small the
dose is.
Ultrasound (1941)
After Pierre Curie discovered piezoelectricity in 1880, ultrasonic waves were able to
be produced and detected and were primarily used in industry settings. The first ultrasonic
echo imaging device was developed in 1940 by Floyd Firestone, and in 1941 the first
ultrasonic echo imaging was performed on the ventricles of the brain (Figure 1.1.2)by
brothers Karl Theo and Friedreich Dussik.11 In the late 1940s ultrasonic energy was used
for medical purposes by Dr. George Ludwig and ultrasound as we know it today was first
used medically to assess the thickness of bowel tissue by John Wild.12

Figure 1.1.2. The first anatomic ultrasound performed.11 It was believed that the hyperphonogram could
depict the ventricles when used on the head.

In this imaging technique13, high frequency broadband sound waves, much higher than
humans can hear, are sent into the tissue and, depending on the tissue composition, will be
reflected back to the probe at different time intervals and to varying degrees. The varying
signal intensities and intervals of return can produce a 3D model in real time. The technique
occurs in three different steps: producing a sound wave, receiving an echo, and interpreting
the echoes. The sound waves used are ultrasonic and are produced with a piezoelectric
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transducer. Short electrical pulses are used to drive the transducer at desired frequencies.
The frequency used depends on the application, but the waves produced are focused using
an array of antennas that allow the direction and depth of the sound waves to be altered and
focused as needed. The focusing of the sound waves produces an arc-shaped sound wave
from the face of the transducer which then travels into the body and comes into focus at a
desired depth.
Once the sound wave enters the body, it is reflected where the body has changes in
acoustic impedance, like blood cells in plasma and small structures in organs. Once the
sound wave reaches a change in impedance, it is scattered and reflected back in the general
direction it came from. In this instance, the transducer, where the signal originated,
becomes the detector. The same method by which the wave was created is used to detect
the returning wave, but in reverse. Thus, the sound wave that returns to the transducer
vibrates the transducer at its returning frequency and the vibrations are turned into electrical
pulses that are transformed into the image seen on the screen of the ultrasonic scanner.
The scanner produces a digital picture by determining how long it took the echo to
respond and how strong the returning echo was. With these two pieces of information, the
scanner can piece together a greyscale image where strong signals are brighter, weak
signals are darker, and the depth of the structure is determined by the amount of time it
took the sound wave to return to the transducer. The image that results is a 2D image,
however, 3D images can be produced by taking consecutive 2D images and digitally
adding them together.
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Ultrasound imaging is utilized most in the diagnosis of diseases and visualization of
structures in fetuses, internal organs, various joints, arteries and veins, and is used to guide
placements in medical procedures. It is a quick, inexpensive, safe technique that allows
good spatial resolution. However, the technique comes with limitations. The sound waves
used in this technique cannot penetrate deep within tissues or pass through bone structures,
so imaging certain deeply embedded areas or bone encompassed areas, such as the brain,
is impossible. This also makes the technique difficult to implement on obese patients with
thicker structures. As a result, this method of imaging is used frequently today as one of
the first imaging modalities in non-threatening cases, and is more frequently used in rural
areas and third world countries as the main source of imaging due to its ease and mobility.
Positron Emission Tomography (PET) / Single-Photon Emission Computed
Tomography (SPECT) (1961)
In 1896, radioactivity was stumbled upon when Henri Becquerel had to postpone
fluorescence experiments with salts and film plates due to overcast skies in Paris. When
Becquerel was able to finally run his experiments, he found that the film plates that he had
prepared days earlier had images on them despite being protected from light sources with
light-proof coatings and being placed in drawers. The images only occurred with one
specific salt and that salt was uranium. Becquerel concluded that the source was the salt
fluorescing, even without an energy source.14 He continued studying the effect and caught
the attention of Polish scientists Marie Curie and her husband Pierre Curie. Marie Curie
coined the term “radioactivity” after observing that uranium was able to electrify the air
around it. The Curies also discovered polonium and radium, which were both more
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radioactive than uranium, and gave future scientists methodologies for detecting
radioactive elements.
The first use of radioactive elements to study the body happened in the 1910s when
George Hevesy used radioactive lead to demonstrate the rate at which the human body
digests food. Through the 1920s, Hevesy continued to use naturally occurring radioactive
lead to study the metabolic processes of plants and animals.15,16 Hevesy co-discovered
hafnium with Dirk Coster in 1922 which lead to the first development of artificial
radioactive elements. Irene and Frederic Joliot-Curie also discovered new artificial
radioisotopes in 1934 and their discovery suggested that new elements could be formed
and potentially made safe. Despite their discoveries, development of radioisotopes used for
medical imaging was largely put on hold during The Second World War when nuclear
energy was being studied and harnessed for use in weapons. When the Manhattan Project
came to a close, scientists were looking for new applications of the nuclear reactions and
the development of nuclear medicine and radiotracers took off until the first conventional
use in the 1960s when the first cerebral PET scan (Figure 1.1.3) was run to determine
localized sensory, motor, and mental functions with 133Xe.17

Figure 1.1.3. The first cerebral PET scan, performed in 1961 with 133Xe.17 This image represents a brain at
rest.

The key to imaging with radioactive isotopes is the use of short lived radiolabeled
tracers or radioisotopes, generally ranging from minutes to hours. The most commonly
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used tracers for imaging are compounds normally used by the body, either during
metabolism or that bind to receptors or sites of drug action and have labelled atoms. Tracers
are generally used to monitor and study biological processes and pathways of the molecules
that are labelled. The most commonly used molecule today is fluorodeoxyglucose (FDG),
which is an analog of glucose that is labelled with 18F. Radioisotopes that are not labelled
atoms as part of a molecule but rather simple soluble ions or part of radio-ligands, can also
be used for imaging. Radio-ligands are preferred because they can transform normally nonspecific radioisotopes into targeted agents to specifically bind to certain types of tissue
which causes the radioisotope to accumulate in desired areas of the body, thereby
increasing the amount of signal seen in the image in that area. FDA-approved radioisotopes
include the following: 11C, 14C, 13N, 15O, 18F, 67Ga, 82Rb, 89Zr, 89Sr, 90Y, 99Mo, 99Tc, 111In,
123

I,

125

I,

131

I, 133Xe, 153Sm,

201

Tl, and

223

Ra. Both labelled radiotracers and radioisotopes

are injected into a patient and the natural decay process of the isotopes occurs inside the
body while detectors monitor the radiation given off from the decay process in order to
create images.
In PET imaging18, the isotopes in the bloodstream undergo positron emission decay
(also known as positive beta decay) and each mechanism results in an emitted positron.
These positrons travel through the tissue of the body until they collide with an electron,
usually within a few millimeters of the decay process. When a positron and an electron
collide, two gamma photons are released in opposite directions (at an angle of 180°). With
the use of rotating gamma-detecting probes detecting in multiple directions concurrently,
the location of each collision that occurs can be mapped and a 3D model can be
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produced/constructed using a computer. In SPECT imaging18, the isotope in the
bloodstream emit gamma rays directly instead of from a secondary source where a positron
and an electron collide. Though the mechanism of decay is different, the detection of the
gamma radiation occurs in the same fashion with rotating gamma cameras and the same
image reconstruction can occur using appropriate computer programs. However, due to the
near-simultaneous detection of the two gamma rays produced in the positron emission
mechanism, PET imaging has higher spatial resolution than SPECT imaging. Though they
result in lower spatial resolution images, SPECT scans tend to cost less than PET scans
and have the ability to utilize longer-lived, more easily obtained radioisotopes than PET.
Since the tracers are injected into the blood stream the tracers follow where the blood
flows. This technique is often performed to identify tissue that have higher blood flow rates
and therefore accelerated growth and metabolic rates, like cancer, metastasis, and
infection.19-24 PET imaging has been used to assess the effectiveness of cancer therapies2527

, psychiatric drug treatments28-32, and anti-atherosclerosis therapies33,34, to examine links

between brain activity and psychological processes29,35-39, to study vascular diseases
including stroke risk and inflammation responses40-45, and to look at musculoskeletal
development46,47. SPECT imaging has been primarily used in functional cardiac and brain
imaging. It has been used to diagnose ischemic heart disease based on the idea that there is
decreased blood flow in the heart and therefore less signal from the heart would be seen in
the images.48-50 With functional brain imaging, information on the cerebral blood flow,
brain metabolism and energy use, and localized brain damage can be attained.51-54
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While this is a powerful imaging technique, it exposes the patient to ionizing radiation,
has low image resolution, and has serious cost and time limitations. Due to the imaging
tracers decaying, they have to be synthesized and utilized relatively close together
(depending on the half-life of the isotope, which ranges from minutes to hours), which
lowers the ability to make and ship tracers to various areas. Also, the synthesis of
radiotracers requires cyclotrons, which are expensive specialized instruments to buy and
maintain.
Computer Tomography (CT) (1971)
In the early 1970s, the X-ray technique got an upgrade from limited direction 2D
imaging to cross sectional 2D imaging and 3D models with the help of computers. The use
of computers in medical imaging was well established by the 1970s with their use in PET
and SPECT imaging, and the improvements being made in technology made the images
created in the computer programs more promising than ever. By combining the X-ray
technique, the PET scanner design, and the advances in technology and computer
processing, Godfrey Hounsfield, an electrical engineer, developed the first CT scanner in
London, England. In October of 1971, the first clinical CT scan was performed on a patient
with a suspected brain tumor.55 The tumor was visible in an 80 x 80 matrix image (Figure
1.1.4) and the surgeon that excised the tumor is reported to have commented that “it looks
exactly like the picture”. It took two years for the first clinical scan to occur in the USA,
but once it was shown how powerful and worthy of a tool it was, CT scanning grew in
popularity and was further developed and the imaging quality improved over the next two
decades.
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Figure 1.1.4. The first CT scan image of a brain tumor.55 The 80 x 80 matrix image took 5 minutes to
acquire.

In X-ray computed axial tomography (CAT or CT) imaging, an X-ray source and
radiation detectors are placed on opposing sides of a rotating platform. The patient is placed
in the center of the instrument so that the body is between the radiation source and
detectors. The platform rotates around the patient, collecting X-ray images in multiple
directions and planes. The X-ray images are then combined using computer programs and,
as a result, a 3D structural representation of the patient can be produced. In this technique,
the use of aforementioned intravenously or orally administered x-ray radiocontrast agents
help in the visualization of soft tissue and the abdomen, respectively. The use of computers
for recreating models of the patient’s anatomy allows for a more meaningful image to be
produced when compared to conventional X-ray imaging alone.
CT imaging is mainly used as a preventative and screening technique, with bone
injuries and lung/chest problems being best suited for non-contrast CT and cancer detection
and tissue differentiation being best suited for contrast CT, though images requiring
contrast often are taken after images without contrast for pre- and post-contrast
comparison. The increased imaging capability of this technique comes with a drawback in
the form of 100 to 1000 times more radiation exposure than that of a conventional X-ray
examination.8 Despite the radiation dose, CT imaging is used primarily in emergent
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situations due to the technique’s fast scan time, good image resolution, and the ability to
image bone structures, soft tissue, and the blood vessels simultaneously with the use of
contrast.
Magnetic Resonance Imaging (MRI) (1977)
In 1937, Isidor Isaac Rabi discovered that an oscillating magnetic field could cause
nuclei to flip their principal magnetic orientation and that the energy absorptions that
occurred when resonance was achieved were detectable and different for distinct atoms.
Rabi coined the phenomena he observed as “nuclear magnetic resonance”.56-58 Edward
Mills Purcell demonstrated similar absorption patterns and observed the NMR
phenomenon while looking at solid paraffin inside an electromagnet with an oscillating
current in 1945.59-62 In 1946, instead of measuring absorption similar to Rabi and Purcell,
Felix Bloch detected a nuclear induction signal from a small water sample in nearby
receiver coils. All three scientists are given credit for the discovery of nuclear magnetic
resonance (NMR), a technique frequently used in chemical analysis and the foundation for
magnetic resonance imaging (MRI).63,64
Raymond Damadian distinguished normal healthy tissue from cancerous tissue in 1971
through NMR analysis. 65 Damadian concluded that the two tissue types contain different
amounts of water which lead to different hydrogen signals, with healthy tissue having less
signal in the analysis because it has less water than tumor samples. Shortly after his
observation, Damadian designed a machine for and applied for a patent for the use of NMR
in distinguishing healthy versus diseased tissue in the human body. Using the same
concepts as described by Damadian in his patent application, Paul Lauterbur produced the
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first NMR image of a test tube in 1973.66 After Damadian built the first MRI scanner with
his graduate students, Damadian took the first MRI scan of a healthy human body in 1977
(Figure 1.1.5) and performed another MRI scan of a human body with cancer in 1978.67-70

Figure 1.1.5. The first MRI image of Raymond Damadian's torso, around T7/T8, performed in 1977.68 The
instrument was only able to produce one-dimensional images due to the instrument’s design.

Magnetic resonance (MR) imaging is a technique that utilizes a strong magnet,
combinations of radiofrequency (RF) pulses, and gradient magnetic fields to manipulate
and detect the proton signal from water in the body, the most abundant nuclei in the human
body at approximately 70%. This signal is spatially encoded by detecting coils and the
information is fed into a computer which can use the data collected, once processed, to
create 2D slices of the anatomy which can be combined to make 3D models. MR imaging
is best suited for soft tissue imaging due to its high water content; thus, the diagnosis of
ligament, tendon, cartilage, spinal cord, and muscle injuries is easily achieved. Depending
on the processing parameters, differentiation of tissue is possible by how much water is
present in each tissue type. The ability to differentiate tissue types can be increased via a
process called tissue weighting. If weighting the images does not provide sufficient
contrast, contrast agents can be administered intravenously. Brain injuries, tumors, strokes,
and any abnormality that results in a change in diffusion across membranes are readily
apparent when contrast media is administered.71-76
The drawback with MR imaging is that the acquisition time is long. This technique
requires compliant patients who lie still through the duration of the examination since any

CHAPTER 1. INTRODUCTION

14

movement changes the spatial arrangement of water and will afflict the spatial encoding of
the signal. Lying still for extended periods of time can be difficult with seriously ill
patients, patients who suffer from claustrophobia, patients who suffer from dementia and
related illnesses, and for patients who are required to lie in uncomfortable positions in order
to get the best images. For this reason, MR imaging is not usually used in emergent
situations, but is capable of producing detailed anatomical images with high resolution.
Comparison of Techniques and Effectiveness
When comparing the different major imaging techniques, each has its own set of
benefits and drawbacks. X-ray images can diagnose skeletal injuries, ultrasound
examinations can give real time information concerning function and structure with
superficial structures and organs, PET/SPECT imaging provides blood flow dependent
metabolic information, CT imaging provides structural information, and MR imaging can
provide structural, metabolic/physiological, and blood flow dependent information. In
order to gather all the meaningful information from imaging to effectively diagnose a
patient, a combination of these imaging techniques is most advantageous to the patient and
their health-care since one imaging technique cannot satisfy all of the possible imaging
requirements.
However, X-ray, CT, and PET imaging all expose the patient to radiation, and
ultrasound imaging has poorer resolution that is restricted to structures close to the surface
of the body which means missing the deeper structures. While MR imaging has long scan
times, as the technique gets more established and is further developed, the acquisition time
may become comparable to that of CT imaging. When the first CT scan was taken, each
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scan run took about five minutes with a similar processing time for an 80 x 80 matrix
image; currently, CT slices are acquired in less than 0.3 seconds and the images produced
can have up to a 1024 x 1024 matrix. The advancement of technology and protocols may
allow for the MRI technique to surpass CT and PET imaging times.
Despite its limitations, MRI provides anatomical, physiological, and blood flow
dependent information from one imaging modality. In order to achieve the same level of
information from imaging data, combining modalities would need to occur. This could be
achieved by utilizing supplementary techniques, such as elastography, tactile imaging,
photoacoustic imaging, thermography, and functional near-infrared spectroscopy (FNIR),
in workups to enhance the aforementioned major imaging techniques. Co-registration of
major imaging techniques to acquire anatomic and metabolic information in one
examination is another current trend in medical imaging. PET-CT instruments have been
increasingly common over previous years and PET-MRI instruments are starting to emerge
as well. However, the combination of PET-CT gives the patient two doses of radiation in
a short amount of time, and the combination of PET-MRI is not necessary since both
anatomical and metabolic/physiological information can be obtained from an MRI exam
alone which renders the PET exam pointless.
1.2.

Nuclear Magnetic Resonance (NMR) and Magnetic Resonance Imaging (MRI)

Spin Dynamics and NMR Theory
Most nuclei have randomly oriented spins that are associated with a small magnetic
moment (I = +/- ½). In the earth’s magnetic field, which is relatively weak, these spins are
randomly oriented in space (Figure 1.2.1). However, when these nuclei are placed into a
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strong external magnet, such as that of an MRI, the spins loosely orient themselves either
with or against the applied magnetic field (Figure 1.2.1), B0, according to the Boltzmann
distribution.

Figure 1.2.1. Spins in a weak magnetic field and a strong magnetic field. Individual spins randomly
oriented in a weak magnetic field (left) and spins aligning with and against a strong magnetic field, B0.

The spins aligned with B0 are distributed in the low energy state, α (+½), and the spins
aligned against B0 are distributed in the high energy state, β (-½). The population of spins
in these two states is nearly equal with a small excess populating the lower energy state.
As B0 is increased in strength, the energy difference between the α and β energy states
increases and the number of spins in excess in the α energy state increases (Figure 1.2.2).

Figure 1.2.2. The Boltzmann distribution, depicting the energy difference between the α and β energy
states and the increasing difference between them with an increasing magnetic field.

The slight excess of spins in the α-energy state per million spins in the body creates a
small magnetic moment (Figure 1.2.3), M0, aligned parallel to the external magnetic field,
B0. The magnitude of the magnetic moment, M0, is directly proportional to the strength of
the magnetic field and is significantly less than B0 and therefore cannot be detected while
aligned with the applied magnetic field.
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Figure 1.2.3. Net magnetization. Individual spins (left) aligned with the magnetic field (red) and aligned
against the magnetic field (blue). The handful of individual spins (right) that make up the net magnetization
signal (green). The vectors on the axes indicate the net magnetizations for each part (red and blue) and the
overall net magnetization for the system (green).

To measure the net magnetization, M0, created by the difference of populations in the
spin states, the system is perturbed using low energy radiofrequency pulses. These RF
pulses, or B1, cause the net magnetization, M0, to end up in the x-y plane where the signal,
Mx-y, can be detected. However, when the spins are pulsed into the x-y plane, they flip
perpendicular to both B0 and B1 and precess in unison according to the Larmor frequency
(Figure 1.2.4).

Figure 1.2.4. Net magnetization in the x-y plane after an RF pulse, B1.

As soon as the spins have been flipped into the x-y plane, and once the radiofrequency
pulse B1 has been turned off, the spins simultaneously begin to relax back to their original
distribution in B0 and lose the coherency that is achieved with B1 (Figure 1.2.5).
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Figure 1.2.5. T1 and T2 relaxation. Signal returning to the z-axis from the x-y plane in T1 relaxation (left)
and signal losing coherency in the x-y plane in T2 relaxation (right).

The former process is longitudinal or spin-lattice relaxation (T1) and the latter is
transverse or spin-spin relaxation (T2). Depending on the type of tissue being imaged,
relaxation rate constants will differ and the rate at which signal is lost in the x-y plane will
change. The differences in both the spin density being manipulated and the relaxation times
of those spins is the basis for spatial 3D imaging. Various RF pulse sequences can also be
applied based on the type of image being taken. In typical MRI exams, differences in water
content are looked at due to the human body being comprised of nearly 70% water and
there being two hydrogen protons for every one water molecule. Other nuclei that can be
probed for diagnostic imaging include 13C, 15N, 17O, 19F, 23Na, and 31P.
MRI Theory
MR images are weighted to increase contrast between tissue types using different pulse
sequences. There are three predominant imaging types (Figure 1.2.6): T1-weighted (T1W),
T2-weighted (T2W), and proton density (PD).
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Figure 1.2.6. T1W, T2W, and PD MRI images.77

In T1-weighted image collection, the fact that different tissues have different T1
relaxation rates is taken advantage of. Once spins are pulsed into the transverse plane, the
spins realign to their natural equilibrium state along B0. However, some tissue types return
to equilibrium quicker than other tissue types. The faster a tissue type’s spins return to
alignment along B0, the more signal that tissue type has when pulsed to the transverse
plane. If a tissue type’s spins return to alignment slowly, not all the spins will be in phase
when repulsed to the transverse plane, and thus that tissue type will have a weaker signal
(Figure 1.2.7).

Figure 1.2.7. T1 recovery curves. Fast (blue), intermediate (green), and slow (purple) T1 recovery curves,
shown with an example of where a new scan pulse would occur. In T1 weighting, the signal intensity at the
time of the pulse is the signal that is kept and the rest of the signal is disregarded.
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This particular signal collection results in fat, protein-rich fluid, and slowly flowing
blood to appear brighter, while bone, air, and higher water content areas appear darker.78
In T2-weighted image collection, the fact that different types of tissue have different T2
relaxation rates is taken advantage of. Once spins are pulsed into the transverse plane, the
spins begin to lose the coherence that was achieved with the RF pulse B1. Some tissue
type’s spins precess around B0 faster than the Larmor frequency and some tissue type’s
spins precess slower. The differences in precessing speeds creates a “smearing out” of the
signals, which causes the signal in the Mx-y plane to decrease (Figure 1.2.8).

Figure 1.2.8. T2 decay curves. Fast (blue), intermediate (green), and slow (purple) T2 decay curves, shown
with an example of where a new scan pulse would occur. In T2 weighting, the signal intensity at the time of
the pulse is the signal that is kept and the rest of the signal is disregarded.

This signal collection results in higher water content areas appearing brighter, while
bone, air, fat, and protein-rich fluid appear darker.78 Proton density (PD) weighted images
combine features from both the T1- and T2-weighted imaging techniques. The tissues that
have the highest density of protons appear the brightest in this imaging technique, so waterrich tissues and fluids in the body will appear bright and moving blood, bone, and air will
appear dark.78 This type of imaging gives high signal distinction between cartilage and
fluid, which makes it highly useful in the imaging of joints. The appearance differences
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inherent in the different tissue types make diagnosis of anatomical abnormalities facile.
The inherent differences in relaxation rates and water densities between tissues do not
always produce enough contrast to see abnormalities. In order to differentiate between
various lesions in the body, an intravenous contrast agent can be administered to create
contrast in the images79-82.
In MRI, T1 contrast agents are utilized to increase the difference in T1 relaxation rates
by shortening the T1 rate constant of water protons directly in the vicinity of the contrast
agent.83,84 The contrast agent is injected intravenously into the patient and travels through
the body via the circulatory system, where it nonspecifically distributes in the intercellular
space in tissues where it can diffuse through the vasculature. In cases where the diffusion
rate through the vasculature is changed, like in malignant tissues with leaky vasculature or
in spots where there are injuries to the vasculature, the contrast agent will be able to move
further into the tissue/area and will affect water that is normally further away from the
effects of the contrast agent. In these cases, physical abnormalities become readily apparent
in the T1-weighted images due to the differences in the T1 relaxation rates. Gd3+ is a
particularly good T1 relaxation metal due to its high isotropic paramagnetism, a
consequence of the 7 unpaired f-shell electrons in the nucleus. Clinically approved T1
contrast agents are derivatives of GdDOTA-1 and GdDTPA-2 chelates (Figure 1.2.9) and,
as such, their function is closely tied to the chemistry of the rare earth lanthanides.
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Figure 1.2.9. Chelate structures. GdDOTA-1 (left) and GdDTPA-2 (right) structures.

Another MRI technique has gained popularity more recently: chemical exchange
saturation transfer (CEST) imaging.85 This imaging modality relies on the detection of
exchange rates for information. This technique offers many advantages over conventional
MRI exams with or without the use of contrast agents. With CEST imaging, contrast can
be turned off if needed, ratiometric imaging is possible86,87, and physiological information
such as pH88,89, temperature88,90, and metabolic information91-93 can be ascertained. This
type of imaging allows for more information to be gathered during an exam than
conventional MRI exams.
In systems where chemical exchange is present, instead of using 90° radiofrequency
pulses to manipulate spin orientations, low power saturation pulses are used to manipulate
the spins that exist in two, or more, exchanging pools. In an exchange system of two pools,
pool A and pool B, if a saturation pulse is applied to pool B the saturation pulse equalizes
the populations in the α and β states which then causes no net magnetization to be present
for pool B (Figure 1.2.10).
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Figure 1.2.10. Saturation mechanism. The non-saturated system (left) and the saturated system (right) after
a long, low power RF pulse (squiggly line) is applied to the system.

The two exchanging pools undergo chemical exchange and the equalized spins move
from a saturated system, pool B, to a non-saturated system, pool A, which lowers the net
magnetization in the non-saturated pool, pool A. Pool B, which still has a saturation pulse
applied to it, then receives non-equalized spins from pool A and the process of saturation
occurs again (Figure 1.2.11).

Figure 1.2.11. CEST mechanism. In all 3 panels: The left side represents the non-saturated bulk pool A and
the right side represents the smaller saturated pool B. The top of each panel depicts the individual spins
associated with each pool in their respective energy states, the center of each panel depicts the actual pools
and shows pool B having the long, low power pulse being applied to it (the affected small molecule appears
green for clarification), and the bottom of each panel depicts the net spins aligned with (red) and against
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(blue) the applied magnetic field, along with the overall net magnetization (green) of each pool. Left panel:
The two pools just before saturation is applied. Center panel: Saturation in pool B is achieved. Right panel:
The saturated water molecule exchanges from pool B to pool A, transferring its saturated individual spins,
and decreasing the overall net magnetization of the bulk pool A. A non-saturated water molecule exchanges
from pool A to pool B, with non-saturated individual spins, to be saturated.

As the process repeats itself the magnetization in pool A is monitored and the change
in magnetization over time can provide information on parameters that affect exchange
rates, like pH, metabolism, temperature, and protein levels. This type of imaging requires
a slow exchange rate to allow for spins to be sufficiently saturated but if the exchange rate
is too slow, the magnetization representing pool A will not change a considerable amount
to be seen in the images taken.
The type of exchange that is monitored can be either proton exchange or small molecule
exchange. Both endogenous CEST agents, or agents that occur naturally in the body
without needing to be injected, and exogenous CEST agents, or agents that are injected
into a patient, can exhibit simple proton exchange from amine, amide, and alcohol moieties
(Figure 1.2.12), and the frequencies associated with these protons (pool B) is within 10
ppm of the bulk water peak (pool A) and their signals are often buried under the water peak
in vivo.
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Figure 1.2.12. Sources of CEST imaging. A. Endogenous CEST source. Top: Protein tertiary structure.
Center: Protein secondary structure showing exchangeable protons (amides are red circles, R groups are
blue circles).94 Bottom: Amino acid R groups with exchangeable protons. B. Small molecule endogenous
CEST source. Glucose, a common endogenous CEST agent used particularly in glucoCEST imaging. C.
Lanthanide series and the shifting capabilities of paramagnetic Ln3+ ions.95 D. Paramagnetic CEST agent
(red) vs. diamagnetic CEST agent (blue).96

Exogenous CEST agents can also exhibit whole small molecule exchange (like water),
or a combination of whole small molecule and simple proton exchange mechanisms. The
frequencies of the exchanging protons and small molecules on the exogenous CEST agents
are also within 10 ppm of the bulk water, unless a shift reagent, or a paraCEST agent, is
used. A paraCEST shift reagent is an anisotropic paramagnetic material that causes a shift
in signal for the species around it (Figure 1.2.12). If a paraCEST agent is used, the
resonance of the protons or associated small molecules can be shifted up to several hundred
ppm depending on which metal is used in the agent. If an exchanging proton is located on
a ligand coordinated to the metal, it will be shifted a certain amount due to the reduced
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shielding from the metal. If a small molecule coordinated to the metal is exchanging, it will
be shifted further down- or up-field due to the fact that it is in closer proximity to the metal.
With paraCEST agents, the increase in shift between the two pools allows for an
increase in water exchange rate for the contrast agent used97-99; however the water
exchange rate still needs to be slow. If the water exchange rate is too fast, the bound water
cannot be fully saturated and the observed CEST effect decreases. Furthermore, in order
for paraCEST imaging to be clinically applicable, the saturation pulses used need to be low
power. At lower power pulse levels, the maximum amount of CEST effect observed occurs
at slower water exchange rates (Figure 1.2.13).100

Figure 1.2.13. Water exchange rate vs. maximum CEST effect achieved at various saturation pulse power
levels.101

Therefore, controlling water exchange rates in MRI contrast agents and slowing it
enough to see CEST contrast is an important goal. Common types of paraCEST agents
used include DOTAM chelates and lipoCEST agents (Figure 1.2.14).
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Figure 1.2.14. CEST agent structure. LnDOTAM+3 structure (left) and lipoCEST agent (right).

DOTA-tetraamide (DOTAM) chelates are DOTA-like chelates with amides instead of
carboxylic acid moieties to coordinate to the lanthanide metal of choosing. Due to the
changes in the coordinating atoms and atoms connected to the coordinating atoms, this
derivative has slightly different chemical properties than DOTA chelates. DOTAM
chelates exhibit slower water exchange rates than DOTA chelates.97,102 This is because the
amide ligand that is being coordinated to the lanthanide ion is a poor electron donor, where
in DOTA chelates the donating ligand is a carboxylic acid. The lanthanide ion, in the
presence of a DOTAM ligand, is considered electron poor and requires more electron
density from the coordinating water molecules; this causes the DOTAM chelate to have
slower water exchange rates as the lanthanide ion holds on tighter to the coordinating water
molecules. Utilizing DOTAM chelates allows a naturally slow water exchange rate and
any changes made to the structure have the potential to further slow or speed up water
exchange. The use of lipoCEST agents involves trapping water inside a phospholipid
bilayer vesicle with a shift reagent and making the water inside chemically different from
the bulk water outside the vesicle.103-106 The water exchange rate in the latter case is
controlled by the type of lipid used to create the bilayer. In either case, the water exchange
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rate is slowed enough for the proper amount of saturation to occur and to be transferred,
and CEST contrast is able to be detected.
1.3.

Contrast Agent Structure and Function

Lanthanides and Gadolinium Chemistry
Although the lanthanides are in a group, each has unique electrochemical properties.
The 4f orbitals are small and buried in the core of the lanthanide ion and, as such, they are
poor at shielding the nucleus and rarely interact with ligand orbitals. Due to the poor
shielding of the 4f electrons there is a gradual increase of attraction between the positively
charged nucleus and the negatively charged electrons with each new proton and electron
added across the series. The attraction causes the phenomenon known as the lanthanide
contraction (Figure 1.3.1).

Figure 1.3.1. The lanthanide contraction.107

Lanthanide ions, across the series, are mainly found in the 3+ oxidation state. 2+ and 4+
states are possible but unlikely since they are unstable due to the reduction potentials
between oxidation states being high and the ionization energies also increasing
dramatically after the third one.
Gadolinium, found in the middle of the lanthanide series, holds particular interest for
use in medical imaging because it is especially stable in the 3+ oxidation state due to the
half-filled 5d and 4f orbital shells (Figure 1.3.2).
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Figure 1.3.2. Electron configuration of Gd+3.108

Due to the half-filled 4f orbital shell, gadolinium is a isotropic paramagnetic metal ion,
meaning that it has a long electronic relaxation time109 and, when used in MRI, shortens
the T1 relaxation times of nearby water molecule protons which enhances the signal of
affected water molecules near the metal.110 However, Gd3+ on its own is highly insoluble
at physiological pH and temperature and is toxic because it is approximately the same size
as Ca2+.111 Therefore it needs to be injected into the body as a chelate rather than as a free
ion so it does not cause circulation problems or get distributed into the bone matrix.
However, choosing an appropriate ligand requires careful thought into the coordination
chemistry of both Gd3+, the coordination chemistry of the ligand, and the desired purpose
of the contrast agent.
Ligand Design and Chelate Structure
All clinically approved contrast agents are derivatives of two contrast agents that
contain polyaminocarboxylate ligands, DTPA and DOTA (Figure 1.3.3).

Figure 1.3.3. Parent ligand structures. DOTA (left) and DTPA (right) ligands. The coordinating atoms are
shown in color for clarification.
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These two ligands both have nitrogen and oxygen donors that coordinate to lanthanide
ions. Since lanthanide ions are hard acids, they prefer to interact with hard bases, such as
oxygen and fluorine, over soft bases, like nitrogen, sulfur, and phosphorus. Nitrogen can
be used as a donor atom, especially if there are oxygen donors present to help displace
water which allows for the nitrogen donor to interact with the lanthanide ion. Due to the 4f
electrons being inaccessible to incoming ligands and the lack of electrons in the 5d shell,
donor ligands as opposed to acceptor ligands are preferred by the lanthanide ions. Both
DTPA and DOTA have amine and carboxylic acid donating ligands, which make them
great ligands for the lanthanide metals.
DTPA and DOTA are also both octadentate ligands. This means that they coordinate
to the lanthanide metal ion through 8 atoms. The coordination number of lanthanide
complexes ranges from 8 to 10 depending on the ligands being used. Coordination numbers
of lanthanide complexes are determined by the size of the metal ion and the size of the
ligand rather than the number of ligands being used or the number of electrons in the
complex. Coordination numbers of 8 and 9 are the most likely to occur in solution.

Figure 1.3.4. Ligand denticity. Monodentate molecules (left) and multidentate ligand (right). The
coordinating atom is shown in color for clarification.
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Monodentate ligands (Figure 1.3.4), or ligands that coordinate to the metal ion through
one site or atom, will afford coordination numbers of 8 or 9 and multidentate ligands
(Figure 1.3.4), or ligands that coordinate to the metal ion through two or more sites or
atoms, can afford a coordination number up to 10, and the larger the ionic radius of the
lanthanide ion the higher the coordination number can be. It’s difficult to achieve
coordination numbers above 9 for monodentate ligands due to inter-ligand repulsions that
may occur, but repulsions due to inter-donor atom interactions can be minimized by using
donor atoms like oxygen or small molecule ligands with small bite angles.
Both DTPA and DOTA exhibit multidentate behavior. Multidentate ligands are more
thermodynamically stable and have higher formation constants than monodentate ligands.
Using a multidentate ligands increases the entropy of the system upon chelation because
once one end of the ligand coordinates to the lanthanide ion, the concentration of the other
end is artificially high and the equilibrium shifts so that the other end of the ligand also
coordinates to the lanthanide ion (Figure 1.3.5).

Figure 1.3.5. Chelation effect.112
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This process is especially amplified when using a macrocyclic system since the ligand
more rigid and is unlikely to distort and move a ligating atom away from the coordination
sphere.113 DTPA is a ligand with a linear backbone and is less thermodynamically stable
than DOTA, which is a ligand with a macrocyclic ring backbone. It is advantageous to
work with systems that are more thermodynamically stable when working with MRI
contrast agents because Ln3+ metal ions are insoluble at physiological pH and temperature
and are toxic when free in the body.111
Chelate Isomerism
When DOTA-like ligands coordinate lanthanide ions, there is a generally a
coordination number of 9; 4 co-planar oxygen donors above the lanthanide ion, 4 co-planar
nitrogen donors below the lanthanide ion, and 1 water coordination site above the oxygen
plane (Figure 1.3.6).114

Figure 1.3.6. Visualizing the chelates. Left: A top-down view of the LnDOTA-1. Center: A side view of the
chelate structure, highlighting the nitrogen, oxygen planes surrounding the Ln+3 metal and the axially
bound water molecule. Right: A visualization of the monocapped twisted square antiprism geometry
DOTA-type chelates exhibit.

The water coordination site is important for the maximum relaxation of water inside
the body and the rate at which the water molecule exchanges on and off of the chelate
(water exchange rate) has an effect on the relaxivity of the contrast agent. The ring adopts
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the lowest energy conformation, which is the ideal 3333 ring conformation (Figure 1.3.7)
for a macrocyclic ring.115

Figure 1.3.7. 3333 ring conformation. This conformation has 4 atoms (3 carbon and 1 nitrogen) and 3
bonds on each side of the square shape.116

The ethylene bridges of the macrocyclic ring have two different chiralities that can be
adopted (δ or λ) in this conformation, and the pendant arms also have two different
chiralities that they can adopt (Δ or Λ). All four macrocyclic bridges will adopt the same
helicity (either δδδδ or λλλλ) and the pendant arms will all adopt the same helicity (either
ΔΔΔΔ or ΛΛΛΛ).117,118 However, the ethylene bridges and the arms do not have to adopt
the same helicity and therefore different combinations of bridge and arm helicity lead to
four isomers available in solution (Figure 1.3.8, Figure 1.3.9)). The square antiprism (SAP)
isomer occurs when the orientation of the arms and the ring are opposed (Λ(δδδδ) and
Δ(λλλλ)) and the twisted square antiprism (TSAP) isomer occurs when the orientation of
the arms and the ring agree (Δ(δδδδ) and Λ(λλλλ)).119
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Figure 1.3.8. SAP and TSAP isomer interconversion.

SAP and TSAP coordination geometries are in dynamic exchange in solution and they
differ only in the angle between the oxygen and nitrogen atoms when looking down upon
the chelate; SAP coordination geometries have a torsion angle close to 40° and TSAP
coordination geometries have a torsion angle close to 25°. The four isomers are in constant
interconversion, and the interconversion between the two coordination geometries is
possible through arm rotations and macrocyclic ring inversions (Figure 1.3.8, Figure
1.3.9).120-122
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Figure 1.3.9. Unsubstituted isomer flowchart. The red arrows indicate interconversion between SAP and
TSAP isomers through arm rotations and the blue arrows indicate interconversion through ring inversions.
The bottom blue arrows are present to show which isomers are converting when the ring inversions occur.

The two coordination geometries also have different chemical properties, with the
TSAP isomer having a water proton exchange rate 50 to 100 times faster than the SAP
isomer due to the elongated cage in the TSAP isomer.102 This means that a solution of any
given contrast agent utilizing the DOTA ligand is a mixture of isomers. MRI scans with
contrast require a large dose of contrast agent (in grams) in order to achieve useful images
and decreasing the dose would be beneficial. Isolating one more effective geometry over
the other less effective geometry could lead to using a lower dose of contrast agent per scan
that is more effective than the mixture of isomers.
The isolation of isomers is possible by utilizing substitutions on the contrast agent cage
and halting the interconversion processes. Upon substitution on the macrocyclic ring, ring
inversions are halted but arm rotations are still available for interconversion (Figure
1.3.10).123 If substitutions are made on the arms, arm rotations are halted but ring inversions
are still available for interconversion (Figure 1.3.11).124 When substitution on the
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macrocyclic ring is used, the substituent is spatially placed in the equatorial position and
the ring ethylene bridges adopt only the δδδδ helicity.

Figure 1.3.10. Ring substitution isomer flow chart. This substitution completely locks out the λλλλ ring
orientation.

When substitution on the pendant arms is used, isomers formed are dependent on the
stereochemical configuration at the α position and whether the arm orientation matches the
orientation of the ring (Figure 1.3.11).

Figure 1.3.11. α position arm substitution isomer flowchart.
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When both substitutions are utilized together, both the arm rotations and ring inversions
are halted, creating isomers which can be separated from one another using HPLC.125-128 It
was expected that only two isomers would be present when both ring and arm substitutions
were utilized, since substitution on the ring allows for only the Λ(δδδδ) and Δ(δδδδ)
isomers to be present. However, it was found that there were actually four isomers. Two
SAP isomers and two TSAP isomers were present in solution, leading to the discovery that
when substitutions are put on the macrocyclic ring, regioisomers develop (Figure 1.3.12).
On the macrocyclic ring, with the 3333 ideal ring conformation, there are side and corner
carbons.126

Figure 1.3.12. Regioisomers flow chart. Utilizing arm and ring substitutions led to the discovery of
regioisomers.

The substituent on the macrocyclic ring will exist in the equatorial position on the side
or corner carbon, and the two regioisomers are not interconvertible unless the metal is
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released from the ligand and re-chelated. Separation of the regioisomers is therefore
possible utilizing HPLC.
In order to ease the synthesis of substituted chelates, the idea of δ substituted arms
controlling arm helicity was suggested. Moving the stereocenter away from the alkylated
carbon (in the α position) would make synthesis easier and it was unknown if the δ position
would control helicity in the same way that the α position did. Substitution at the δ position
of the arm does not halt arm rotations but may play an important role in where the arm
substituent resides in space.129 The substituent’s position in space starts in a pseudoequatorial position, with the arm helicity conforming (Figure 1.3.13).

Figure 1.3.13. Delta substitution effects. The substituent’s placement in space affects the water exchange
kinetics of the chelate.

Arm rotations still occur with δ position substitutions and the arm may rotate to a
different helicity, which then moves the substituent to a pseudo-axial position (Figure
1.3.13). If the substituent is a hydrophobic moiety and located in the pseudo-axial position,
closest to the water exchanging site, water exchanging on and off of the chelate is slowed
since the water has to get past several hydrophobic substituents. If the hydrophobic
substituent is located in the pseudo-equatorial position, the exchanging water is farther
away from the hydrophobic moieties and can exchange without interference. The opposite
is true if the substituent is hydrophilic. Hydrophilic substituents in the pseudo-axial
position increase the water exchange rate of the chelate because the moieties increase the
amount of water molecules in the pool of water near the exchanging site, and hydrophilic
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substituents in the pseudo-equatorial position decrease the number of waters in the pool of
water near the exchanging site by moving them farther away from the site and therefore
decreases the water exchange rate of the chelate. The first part of this work looks
specifically at what happens in these DOTAM systems when the substituent is hydrophobic
instead of hydrophilic.
1.4.

Progressing the MRI Technique

Theory
The medical imaging field is constantly developing and improving, and the MRI
technique is extremely versatile due to that constant development. Along with the typical
T1-, T2-, and PD-weighted images that are generally taken in MRI exams, special exams,
specialized contrast agents, and a wide range of pulse sequences make the technique quite
powerful.
Diffusion MRI exams diagnose stroke and multiple sclerosis by measuring the
diffusion of water in various tissues, MR angiography (MRA) and MR venography (MRV)
(Figure 1.4.1) exams evaluate the arteries, veins, and blood flow of the patient and whether
or not stenosis or aneurysms are occurring130-133, functional MRI (fMRI) exams (Figure
1.4.1) claim to detect increased blood flow and as a result show which part of the brain is
being stimulated and used during different tasks or during emotions31,52,134,135, and MR
spectroscopy (MRS) exams (Figure 1.4.1) can detect changes in biomarkers in tissues and
can help to diagnose gliomas, non-glial tumors, infection, ischemia and infarctions,
mitochondrial disorders like Leigh syndrome, hepatic encephalopathy, and white matter
diseases like progressive multifocal leukoencephalopathy (PML) and Canavan
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disease.78,136-140 Each exam type utilizes different pulse sequences to look specifically at a
wanted signal and to disregard the other signals present. Real-time MRI has been a
development goal for several decades and is often called FLASH MRI (fast low angle shot
magnetic resonance imaging).141 This type of exam has been able to shorten the length of
exam times, yields 3-dimensional representations of vasculature and complex anatomic
structures like the brain and joints, and has been used to create movies of beating hearts
and to guide minimally invasive surgical procedures in interventional MRI.

Figure 1.4.1. Specialized MRI exams. Left: MRA image.142 Center: fMRI images.143 Right: MRS exam
results.144

Specialized contrast agents can be used to enhance contrast or to target the exam to a
specific part of the body. Specialized MRI contrast agents include responsive agents86,145150

, active targeting agents151-155, organ specific agents156-158, and pH-sensitive agents148,159-

165

. These various agents can turn on or off if enzymatically cleaved, can indicate if certain

metabolites or metals are present in the body, can target organs, tumors, cells, proteins, and
antibodies, and can indicate pH, temperature, or oxygen levels in the body. The combined
power of specialized exams and targeted agents means that MRI as a diagnostic tool can
be extremely powerful. With the advancement of the exams and the contrast agents used,
the analyses of the data are increasingly difficult and require quite a bit of manipulation
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and fitting of the signal data to mathematical expressions and comparing to collected
laboratory data.
Currently, parameters that are used for fitting the data collected to make images and
maps vary and there is no one method. In fact, there are many different methodologies for
calculating information from data collected and there are many assumptions that go into
fitting the data. For example, when utilizing CEST imaging to determine the pH of a
sample, the following are the parameters needed for one type of calculation: the RF
labelling coefficient, the spillover factor, the chemical exchange rate from labile protons
to bulk water protons, the ratio of labile protons to the bulk water protons, and the intrinsic
longitudinal relaxation rate of bulk water. The labelling coefficient and spillover factor are
calculated from the power levels and offset of the RF irradiation, the labile proton
frequency, the exchange rate, and the apparent longitudinal and transverse relaxation times.
Determining all of the parameters is often difficult or not possible and assumptions for
some of the parameters have to be made to make the calculation work so relevant
information can be extracted from the image. The above is only one method for calculating
pH utilizing a CEST agent, and there are many different calculations and approaches that
researchers have come up with.148,159,160,164,166-177 Each method has its own list of
parameters, some being held and some being allowed to fluctuate in calculations.
Determining which parameters to hold constant and which to allow to be fluid, and having
that protocol be universal, doesn’t seem to be as big of a goal as it should be.
Compartmentalization is another problem that should be addressed with the
advancement of the MRI technique. Calibration curves and information used in the
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determination of relevant information, like pH and temperature, are often generated in a
lab setting inside test tubes, beakers, phantoms, and NMR tubes. These environments are
free of compartmentalization, where the agents in question have free access to water and
other molecules present in testing solutions. In vivo environments are very limited
environments with separated compartments as opposed to a homogenous solution. The
comparison from one to the other is a gross error. Exchange rates where the chelate has
unlimited access to water will give you accurate information for that system, and that
system only. Trying to apply the open system’s information to a different system where
the chelate has limited access to water will not give you accurate results, which leads to
inaccurate pH and temperature maps and erroneous values.
Compartmentalization in the laboratory setting should allow for a controlled
encapsulated environment where chelates have access to a limited amount of water.
Analyzing chelates in this system should lead to more accurate values being produced from
data collected. Understanding the full mechanism of exchange and how that process affects
the information gained from collected data is vital. The second part of this work looks at
the encapsulation of contrast media inside phospholipid vesicles and understanding the
effects of water exchange across the membrane.
Internal CEST
While the second part of this work could have a global application on the MRI field, it
also has a more focused goal. Encapsulating the contrast agent inside a phospholipid
bilayer has the potential to slow and control water exchange kinetics depending on the
lipids chosen for the vesicles. This method for controlling water exchange rates in chelates
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involves looking at affecting the environment that the chelate sees instead of changing the
ligand of the chelate. By encapsulating a paraCEST chelate within a semipermeable
membrane, like a phospholipid bilayer, the chelate would only “see” the water that is inside
the vesicle.178 Regardless of whether the water exchange rate of the chelate, kc, is fast or
slow, the observed water exchange rate, kd, will be slow due to the slow diffusion of water
across the phospholipid bilayer membrane (Figure 1.4.2). This slow exchange would allow
relaxed water protons to move out into the bulk water at such a slow rate that the observed
water exchange rate would be significantly slower than what would be expected with just
the chelate and allows for improved contrast. Here, the water exchange rate of the chelate
isn’t actually changed, but the observed water exchange rate is. This methodology allows
for a more facile manipulation of the water exchange rates. The steps of encapsulating
chelates inside phospholipid bilayers take significantly less time and eliminate lengthy and
difficult organic syntheses. However, there are variables that should be considered in the
design of the encapsulation system.

Figure 1.4.2. Internal CEST mechanism.
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Vesicles 101

Lipid Structure and Function
Lipid composition is picked based on desired characteristics of the system. Generally
the lipids have a hydrophilic phosphate head and a hydrophobic tail that contains two fatty
acid chains (Figure 1.5.1).

Figure 1.5.1. Lipid structure and phospholipid bilayer.179

The head groups have the ability to change the surface chemistry of the vesicle, can
serve as a site for anchoring targeting molecules, or can also be signals for other molecules.
Sphingolipids are an example of a particular polar head group that provides a charged
group on the surface of the liposome. Phosphatidylserine (PS) is a signal for cell apoptosis
in mammalian red blood cells180, but when it is incorporated into growth plate vesicles it
aids in bone mineralization181. The head groups determine how the vesicle interacts, or
doesn’t, with its surrounding environment.182,183
The tails of the lipid have the ability to affect the liposome’s membrane properties
based on the length of the tail, the chemical properties of the tail, and whether or not the
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chains of the tail are saturated or unsaturated. Whether or not the lipid tail is saturated or
unsaturated will affect the packing of the tail inside the bilayer and affects the liposomes
resistance to stressors, like stretching or bending.184-188 The length of the chain will also
affect the packing ability of the lipid tails, with longer tails requiring more bending and
folding to fit inside the bilayer.184-188 The chemical properties of the tail will determine the
transition temperature for the bilayer (Table 1.5.1). Below the transition temperature, the
bilayer adopts a solid gel phase, while above the transition temperature the bilayer will
enter into a fluid state.189-202 The solid gel phase makes the liposomes more stable and better
able to handle stresses by locking in the lipids and limiting their mobility, which also in
turn makes the exchange rate across the membrane slower. Being above the transition
temperature during formation allows lipids to diffuse and move within the membrane203,
which allows the vesicle to be manipulated into the desired size and lamellarity. Tail length
can affect the transition temperature, with longer chains having more surface area available
to interact with other tails which decreases the lipid mobility and has a higher transition
temperature. Saturation also affects the transition temperature, with unsaturated lipids have
disrupted packing within the layer which creates more mobility, and in turn decreases the
transition temperature.
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Table 1.5.1. Phospholipid transition temperature.204

Phospholipids are used as the primary composition of vesicles. Naturally occurring
phospholipids (Figure 1.5.2) include phosphatidylcholine (PC), phosphatidylethanolamine
(PE), phosphatidylserine (PS), phosphatidylinositol (PI), and phosphatidylglycerol (PG).
These are general lipid names and are either saturated or unsaturated.
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Figure 1.5.2. Naturally occurring phospholipid head groups.

Commonly used saturated lipids (Figure 1.5.3) are generally dipalmitoyl derivatives of
the aforementioned phospholipids: dipalmitoyl phosphatidylcholine (DPPC), distearoyl
phosphatidylcholine (DSPC), dipalmitoyl phosphatidylethanolamine (DPPE), dipalmitoyl
phosphatidylserine (DPPS), dipalmitoyl phosphatidic acid (DPPA), and dipalmitoyl
phosphatidylglycerol (DPPG).
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Figure 1.5.3. Saturated lipids. Examples of saturated lipids.

Commonly used unsaturated lipids (Figure 1.5.4) are dioleoyl derivatives of the
aforementioned phospholipids: dioleoyl phosphatidylcholine (DOPC) and dioleoyl
phosphatidylglycerol (DOPG).

Figure 1.5.4. Unsaturated lipids.

To increase the bilayer stability and decrease the fluidity of the membrane, sterols, like
cholesterol, can be incorporated into the liposome bilayer. Cholesterol (C) (Figure 1.5.5)
intercalates into the bilayer between the tails of the phospholipids and reduces the
permeability of the membrane to water soluble molecules.190,205-209
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Figure 1.5.5. Cholesterol structure.

Vesicle Classification and Preparation
Phospholipid vesicles can be classified in three ways: by structural parameters, by
method of preparation, or by composition and application. The structural features that
classify a vesicle are the lamellarity and the size of the vesicle. The lamellarity of a vesicle
is determined by the number of bilayers that make up the vesicle and the number of aqueous
compartments. If the vesicle is made up of one bilayer that surrounds one aqueous
compartment, then the vesicle is considered to be a unilamellar vesicle (ULV). If the vesicle
has one internal compartment but is made up of 2 or more bilayers stacked on top of each
other, then the vesicle is considered to be an oligolamellar vesicle (OLV). If the vesicle has
several bilayers and has several compartments on the inside of the vesicle, then the vesicle
is considered to be a multilamellar vesicle (MLV) (Figure 1.5.6). The size of vesicles
ranges from 10 nm to several μm. Vesicles that are generally between 20 and 40 nm are
considered small vesicles, 40 to 80 nm size vesicles are considered medium vesicles, and
vesicles between 100 nm and 1 μm are considered large vesicles. Generally, ULVs can be
small (SUV), medium (MUV), and large (LUV) (Figure 1.5.6), while MLVs are usually
LUVs or OLVs enclosing a large number of SUVs.
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Figure 1.5.6. Vesicle classification.210

Vesicles can be classified by the method of preparation, which can influence the size
and lamellarity of the vesicles. Each method below begins by dissolving the lipid mixture
in chloroform, or some other similar solvent, and removing the solvent under reduced
pressure so that the lipid is dried into a thin layer on the glassware (typically a round bottom
flask). After that, the method of formation of vesicles differs and generally ends with an
extrusion process to control the size of the sample. Generally though, when the thin films
are hydrated with aqueous medium, MLVs form with 5-10% of the aqueous volumes
enclosed within the lipid membranes. Lipids have polar, hydrophilic head groups and
nonpolar, hydrophobic fatty acyl chains. The vesicles form spontaneously due to the
hydrophobic effect, where the hydrophobic tails folding against one another increases the
entropy of the system, causing more tails to continue interacting while the hydrophilic head
groups are placed on the outer areas of the bilayer in contact with the aqueous medium
(Figure 1.5.7). Other working forces in the formation of the vesicles include van der Waals
forces, electrostatic forces, and hydrogen bonds.
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Figure 1.5.7. Vesicle formation mechanism.211

Forming vesicles can be done in a number of ways, however, forming the vesicles and
having some control over the size of the vesicles is typically done with either extrusion or
sonication.212 Sonicating at certain frequencies will influence what size the vesicles
generally are, with faster frequencies making smaller vesicles and slower frequencies
resulting in larger vesicles. Extrusion is a much more precise method for controlling the
size of the vesicles. The extrusion apparatus used can either be manual (two syringes on
either side of porous filters, operated with your hands) or it can be a pressurized system
that uses inert gas to force the sample through the porous filters. The porous filters are
polycarbonate membranes that are whatever size is desired for the vesicles being made.
Sonication and extrusion are used to make homogenous samples and can be used in
combination with each other, with other methodologies, or on their own. Both techniques
can make ULVs with tunable small size distributions.

CHAPTER 1. INTRODUCTION

52

The reverse-phase evaporation method212 involves suspending the desired lipid mixture
in an organic solvent, like diethyl ether or isopropyl ether, so that the reverse phase vesicles
are formed with the polar heads on the inside of the bilayer and the nonpolar tails on the
outside of the bilayer. The aqueous phase is added to the mixture, forming a two-phase
system which is sonicated briefly until the mixture becomes either a clear one-phase
dispersion or a homogenous opalescent dispersion. The organic solvent is then removed
under reduced pressure, leaving only the aqueous mixture with formed vesicles. The
vesicles can then be extruded to the desired size. If the vesicles formed are SUVs or OLVs,
the vesicles are called REV vesicles. If the vesicles formed are MLVs, the vesicles are
called MLV-REV vesicles.
The freeze-thawed preparation212 involves hydrating the thin layer with the aqueous
solution or buffer and vortexing the sample to emulsify the lipid mixture. The container
that the sample is in is then dipped in liquid nitrogen for some time and then placed in a
hot water bath at some temperature for thawing for some time. The time frames picked can
differ based on the paper, but generally the samples are frozen and heated for the shortest
amount of time, and the temperature of the hot water bath should be above the transition
temperature of the lipid mixture. The freeze-thaw cycle is repeated for a designated number
of rounds, usually 10. After this process is completed, the samples are either extruded or
sonicated to further form the vesicles and control the size and lamellarity of the vesicles.
However, the process of freeze-thawing seems to form predominately unilamellar vesicles,
and vesicles made using this technique are called FAT-ULVs.
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The dehydration-rehydration process212 involves hydrating the thin film of lipid with
the aqueous solution or buffer, and then extruding the sample to the desired size. After the
extrusion process, the formed liposomes are dehydrated by freeze-drying for some time
until the sample is dry, which typically is 24-26 hours. The dehydrated liposomes are sealed
and stored at 4°C, if desired, then brought back to room temperature and slowly hydrated
again with the buffer being used, with small increments of buffer being added over an hour
at a temperature above the transition temperature of the lipid mixture. This method also
produces predominately unilamellar vesicles, and the formed vesicles are called DRVs.
The third classification category is composition and application. This depends on the
charge of the lipid, but certain lipid combinations have been identified as excellent
targeting systems and are then classified by the use of the vesicle. If the lipids being used
contain neutral or negatively charged phospholipids, with or without added cholesterol, the
vesicles are called conventional liposomes (CL), and if the lipid mixture contains cationic
lipids then the vesicles are called cationic liposomes.213 Fusogenic liposomes (RSVE) are
made from reconstituted Sendai virus envelopes, which makes them good drug delivery
systems that deliver to the cytoplasm in an endocytosis-independent way.214-217 Long
circulatory liposomes (LCL), or stealth liposomes, are liposomes that have PEG derivatives
attached to the surface of the liposome.218-221 The PEG derivatives decrease the detection
by phagocyte systems, which allows the liposomes to have an extended circulation time in
the body. Immune-liposomes are either CLs or LCLs that are targeted with monoclonal
antibodies or other recognition sequences on the surface of the liposome.222-225 pH sensitive
liposomes are also possible with the right mix of lipids. These vesicles are systems that fall
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apart when they encounter a certain pH in the body.226-231 These systems are often used in
combination to get the best system for the desired application.
Vesicle Characterization
Vesicle shape can be visualized using electron microscopic techniques, while
lamellarity of the vesicle can be evaluated using freeze-fracture electron microscopy and
31

P NMR. The size and size distribution of the sample can be determined using many any

or all of the following methodologies: light microscopy, fluorescent microscopy, electron
microscopy (particularly TEM), laser light scattering photon correlation spectroscopy,
field flow fractionation, gel permeation, and gel exclusion. Laser light scattering methods,
like dynamic light scattering (DLS), is the most simple and rapid methodology and
measures an average property of the bulk liposomes. TEM and other electron microscopy
techniques are the most precise method for size determination because it allows the
visualization and measurement of individual liposomes (Figure 1.5.8); however, electron
microscopy techniques are often time consuming and the equipment is not always
available.

Figure 1.5.8. TEM image of MLVs.232
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Checking the encapsulation efficiency of the liposomes is usually performed by
trapping a compound of interest inside the vesicles, removing free compound not in the
vesicles by dialysis, and then destroying the vesicles and measuring how much of the
desired drug or agent is present as compared to the amount that was initially attempted to
load when the vesicles were formed. The volume entrapped in the agent can be determined
by loading a fluorescent probe into the vesicles, removing free fluorophore from the
solution by dialysis, then freeing the fluorophore and measuring the concentration of the
probe. The encapsulation efficiency and entrapped volume methods assume that the
liposomes are unilamellar. NMR analysis can also provide information concerning the size
of the vesicles if a shift reagent is loaded into the liposomes, free shift reagent is removed
by dialysis, and then measuring the area under the two peaks representative of the aqueous
medium with and without the shift reagent (Figure 1.5.9).

Figure 1.5.9. Intraliposomal NMR analysis.233

1.6.

Scope of This Work
The overall goal of this work was to explore water exchange kinetics and to sow water

exchange in two different systems. The first system studied was a rigid Ln3+ NB-DOTAM
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chelate with hydrophobic amide substituents. The chelate studied was similar to a
previously studied chelate with hydrophilic amide substituents, which allowed for
comparison between the two moieties and their effect on the amount of CEST signal that
was seen. The second system studied was a phospholipid bilayer system that had various
parameters changed to try to optimize the water exchange rate across the membrane. A
second vesicle system was minimally studied when the first system failed to produce a
slow water exchange rate, however studies on the second system were difficult and
parameters were not optimized for the system.
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CHAPTER 2. STRUCTURAL MANIPULATION PROJECT
2.1.

Isomer Notation
In general, the notation of chelates used would go as follows:

"corner "

Λ δδδδ

Axial

Ln

Where:
"Regioisomer from NB Substitution "

Arm Orientation Ring Orientation

! "# $ %&'()(%*+( (*#*",-*.)'(#/
δ Substituent Position, if present

Metal 456789

However, for simplicity, there is a shorter notation that will be used from here forward.
The above chelate will be carried forward as an example and a structure of the chelate is
given in Figure 2.1.1 for reference.

Figure 2.1.1. Reference chelate for naming notation, “corner”-Λ(δδδδ)-SSSS-Axial-Ln4.

By substituting on the macrocyclic ring with a nitrobenzyl group, the λλλλ orientation
of the ethylene bridges is locked out due to the pro-S positioning of the substituent and
only the δδδδ orientation is available for chelate formation. Therefore, the (Ring
Orientation) notation is removed, to give:
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Axial

Ln

The substitution on the macrocyclic ring also leads to two possible regioisomers
(Figure 2.1.2), a side regioisomer (denoted by “s”) and a corner regioisomer (denoted by
“c”). Therefore, the “Regioisomer from NB Substitution” is shortened from the word
“corner” to “c”, to give:
"c "

Λ

Axial

Ln

Figure 2.1.2. Substitution positions.

The substitution at the α position on the pendant arm (Figure 2.1.2) controls the
coordination geometries, where matching arm and ring orientations lead to TSAP isomers
(S@α gives Δ(δδδδ); denoted by Δ) and opposing arm and ring orientations lead to SAP
isomers (R@α gives Λ(δδδδ); denoted by Λ). This means that the Arm Orientation will be
left as Λ (representative of opposing arm and ring orientations, or SAP isomers), to give:
"c "

Λ

Axial

Ln

Substitution at the δ position (Figure 2.1.2) does not halt arm rotations but plays a role
in where the arm substituent resides in space. Whether the substituent is found in a pseudoaxial (denoted by Ax) or pseudo-equatorial (denoted by Eq) position (Figure 2.1.3) is
dependent on the stereochemical configuration at the δ position and the helicity of the arms.
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However, the stereochemistry at the δ position is given by which ligand is used (1, 2, 3, or
4 – 1 and 3 have the RRRR stereochemistry at the δ position and 2 and 4 have the SSSS
stereochemistry at the δ position). This means that the δ Substituent Stereochemistry
notation SSSS can be removed, to give:
"c "

Λ

Axial

Ln

And the δ Substituent Position (Figure 2.1.3) can be shortened to Ax (pseudo-axial) or
Eq (pseudo-equatorial) to show where the substituent is located in space, to give:
"c "

Λ

Ax

Ln

Figure 2.1.3. Pseudoaxial and pseudoequatorial positions in space.

This condensed notation form will be used for all chelates in this chapter, and a
flowchart can be found in Figure 2.1.4 and 2.1.5 to help in the identification of isomers
discussed.

Figure 2.1.4. Isomer naming flowchart.

In order to look at the effect of substituting at the δ position on isomer distribution, a
thorough study on a handful of lanthanide NB-DOTAM chelates was undertaken. Both
hydrophilic (carboxylic) and hydrophobic (phenyl) δ position substituents were studied for
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their effect on water control and CEST effect. The carboxylic chelate studies were
performed previously and served as motivation for the phenyl chelate studies. Both types
of chelates were substituted on the macrocyclic ring with a nitrobenzyl (NB) substituent to
lock out ring inversion conversion between SAP and TSAP isomers, and the chelates were
also substituted on the pendant arms with a methyl group at the δ position in hopes of
stopping arm rotation conversion between SAP and TSAP isomers. Both chiralities of the
pendant arm substitution were synthesized and therefore both the RRRR and SSSS ligands
were investigated. Figure 2.1.5 can serve as a “cheat sheet” for tracking the structures of
the chelates 1, 2, 3, and 4, and for visualizing the results of the experiments, as indicated
by the different colored boxes. The flowcharts are included throughout the chapter to help
keep isomers straight and to help organize the data and results.

Figure 2.1.5. Flowchart “cheat sheet”. The boxes with bold black outlines represent isomers that were not observed at all in the NMR studies. The boxes with
bold blue outlines represent isomers that were observed in the Ln1 and Ln3 chelates. The boxes with bold purple outlines represent the isomers that were
observed in the Ln2 and Ln4 chelates. The boxes with the bold red outlines represent the isomers that grew into the sample as the lanthanide series was
crossed in the Ln2 and Ln4 chelates.
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Motivation – Carboxylic Derivatives234

Figure 2.2.1. Carboxylate Ln3+DOTAM chelates studied.

Basic NMR Studies

Figure 2.2.2. Ln1/2 1H NMRs.

Ln1 and Ln2 were chelated with Pr3+, Eu3+, and Yb3+ ions (Figure 2.2.1). NMRs were
taken of all chelates to identify isomers present in solution. Isomers are differentiated in
NMR by the shift of their axial protons on the macrocyclic ring. SAP isomers are highly
shifted downfield by their proximity to the metal ion. With TSAP isomers, the ligand field
is smaller which leads to less shifted axial protons on the macrocyclic ring. When looking
at Ln1 across the series (Figure 2.2.2), only SAP isomers were present in the Pr3+, Eu3+,
and Yb3+ chelates (Λ-Pr1/Eu1/Yb1). Ln2 showed only TSAP isomer in the Pr3+ chelate (ΔPr2). As the ionic radius of the metal ion complexed with the ligand decreased in size, the
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isomer distribution shifted from pure TSAP isomer to a mix of SAP and TSAP isomer.
When looking at the Eu3+ chelate, it appeared that only TSAP isomer was present (Δ-Eu2),
but upon closer inspection a small amount of SAP isomer was identified in solution (ΛEu2). The amount of SAP isomer increased with the Yb3+ chelate. This indicated the SAP
isomer was preferred for the smaller Ln3+ metal ions found at the end of the lanthanide
series, indicating that the coordination cage is smaller for SAP isomers than TSAP isomers,
but also indicating that the δ position substitution on the pendant arm had very little control
over arm helicity. The δ substituent suggested that Ln1 isomers have a low energy
geometry (SAP) with the substituent in a low energy position (pseudo-equatorial), giving
only the following isomers in each sample: Λ-Eq-Pr1/Eu1/Yb1. (Figure 2.2.3) However,
with the reversed stereochemistry, Ln2 adopted the reversed arm helicity and appeared as
a high energy geometry (TSAP) with a low energy substituent position, giving only the ΔEq-Pr2 isomer in the beginning of the lanthanide series (Figure 2.2.3). However, moving
across the series forced Ln2 to place the substituent in a higher energy position (pseudoaxial) so the geometry could be a lower energy configuration (SAP) for some of the sample,
giving the following isomers: Δ-Eq-Eu2/Yb2 and Λ-Ax-Eu2/Yb2.
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Figure 2.2.3. Ln1/2 NMR flowchart. High and low energy conformations are indicated.

CEST Experiments

Figure 2.2.4. Eu1/2 CEST spectra.

CEST experiments were performed to explore the water exchange rates of each
europium chelate prepared (Figure 2.2.4). The Eu1 and Eu2 chelates had CEST peaks
appear, but with varying intensities and only for the SAP isomers (Λ-Eq-Eu1 and Λ-Ax-
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Eu2). TSAP isomers don’t usually appear in CEST spectra due to their water exchange
kinetics being faster than what is ideal for CEST. SAP isomers, having slower water
exchange kinetics, do appear in CEST spectra. The open diamonds, the largest CEST peak
obtained, represent Eu1 with a Λ-Eq-Eu2 isomer concentration of 274 μM. The open
circles, the middle CEST peak obtained, represent Eu2 with a Λ-Ax-Eu2 isomer
concentration of 13.7 μM. The concentration of SAP isomer for Eu1 is much greater in
these two cases, therefore a third CEST experiment was run with the concentration of the
Λ-Eq-Eu1 isomer equal to 13.7 μM (closed circles). A comparison could then be made
between the Λ-Eq-Eu1 and Λ-Ax-Eu2 isomers. The Λ-Eq-Eu1 sample with the
concentration of 13.7 μM had no effective CEST peak arise in the spectrum. This means
that the Λ-Ax-Eu2 isomer has a water exchange rate appropriate for CEST imaging while
the Λ-Eq-Eu1 isomer does not, which means that the water exchange rate for the Λ-AxEu2 isomer is comparably slower than that for the Λ-Eq-Eu1 isomer.

Figure 2.2.5. Eu1/2 Omega plots. Omega plots were used for calculating water exchange rate of the
chelates.

However, after omega plots were used to analyze the spectra over varying pulse power
levels (Figure 2.2.5), the water residence lifetime for the Λ-Eq-Eu1 isomer was found to
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be 116 μs, while the water residence lifetime for the Λ-Ax-Eu2 isomer was found to be 65
μs. Therefore, the Λ-Eq-Eu1 isomer has a slower water exchange rate, possibly too slow.
This suggests that the chirality of the δ substitution has some effect on the water
exchange kinetics seen in the chelates due to the spatial arrangement of the amide
substituent (Figure 2.2.6). With the Λ-Eq-Eu1 isomer, the carboxylic acid group is in a
pseudo-equatorial position and has slow water exchange not ideal for CEST imaging. This
could be due to the pseudo-equatorial carboxylic acid attracting water away from the water
exchange site. Water exchange on and off of chelates is a dissociative mechanism, so if the
pool of water to exchange with is low, then the chelate would hold onto the water it is
coordinated with longer than normal. If the pool of water near the exchange site was full,
then the lanthanide would have no reason to hold onto the coordinated water for as long
since another water would quickly replace the one it would lose. The Λ-Ax-Eu2 isomer
has the amide substituent in a pseudo-axial position, and presumably has a larger pool of
water molecules near the exchange site, making the water exchange rate speed up to a rate
that is ideal for CEST imaging.
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Figure 2.2.6. Eu1/2 CEST flowchart. Found τm values are indicated.

The spatial arrangement could be affecting the water exchange rates for the Λ-Ax-Eu2
isomer by creating a pool of water around the hydrophilic groups, which would then
exchange with the chelate and put affected water molecules back into the pool around the
substituents. The exchange between the pool around the substituents and the bulk water in
the sample could be slow in the Λ-Ax-Eu2 isomer due to the attraction of the water to the
hydrophilic amide groups, creating an artificially slow water exchange rate even though
the pool around the exchange site is larger, which could be giving the Λ-Ax-Eu2 isomer
its impressive CEST signal. This hypothesis lead to the next NB-DOTAM chelate studied
to have hydrophobic amide groups instead of hydrophilic groups.
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Studied Chelates – Phenyl Derivatives235

Figure 2.3.1. Phenyl Ln3+DOTAM chelates studied.

Basic NMR Studies

Figure 2.3.2. Ln 3/4 1H NMRs. The scale follows conventional NMR convention where downfield is to the
left.

Ln3 and Ln4 were chelated with Ce3+, Pr3+, Nd3+, Sm3+, Eu3+, Tb3+, Dy3+, Ho3+, Er3+,
and Yb3+ ions (Figure 2.3.1). Isomers are differentiated in NMR by the shift of their axial
protons on the macrocyclic ring. SAP isomers are highly shifted downfield by their
proximity to the metal ion. With TSAP isomers, the ligand field is smaller which leads to
less shifted axial protons on the macrocyclic ring. Ln3 chelates all adopted the SAP
geometry (Λ-Eq-Ln3) with no change of coordination geometry as the ionic radius of the
lanthanide ion decreased, just like the Ln1 chelates (Figure 2.3.2). However, it was noted
this time around that two different regioisomers were present in solution due to the
nitrobenzyl substituent being present on both the side and corner position of the
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macrocyclic ring, giving “s”-Λ-Eq-Ln3 and “c”-Λ-Eq-Ln3 isomers. Ln4, as seen with Ln2,
started with all TSAP geometry (Δ-Eq-Ln4) present in the early lanthanides, but as the
ionic radius decreased across the lanthanide series the amount of SAP coordination
geometry (Λ-Ax-Ln4) present in the samples increased and the ratio between SAP isomers
and TSAP isomers increased (Figure 2.3.2). Again, the emergence of SAP isomers in the
Ln4 chelates supports the idea that the δ position substitution does not control which isomer
is formed in solution and does not lock arm rotations to cease interconversion between
isomers.
As seen with the Ln1 and Ln2 isomer trends, the δ substituent suggested that Ln3
isomers have a low energy geometry (SAP) with the substituent in a low energy position
(pseudo-equatorial), giving only the following isomers in each sample: Λ-Eq-Ln3 (Figure
2.3.3). However, with the reversed stereochemistry, Ln4 adopted the opposite arm helicity
and appeared as a high energy geometry (TSAP) with a low energy substituent position,
giving only the Δ-Eq-Ln4 isomer with the early lanthanides (Figure 2.3.3). Moving across
the series forced the Ln4 chelate to place the substituent in a higher energy position
(pseudo-axial) so the geometry could be a lower energy configuration (SAP) for some of
the sample, giving the following isomers: Δ-Eq-Ln4 and Λ-Ax-Ln4 for the latter half of
the lanthanides used. Not observed with the Ln2 isomers though, were the presence of
regioisomers. Both side and corner regioisomers were observed in the Ln4 chelates (similar
to the Ln3 chelates), giving the following 4 different isomers present in solution starting
around Eu4 and continuing through the end of the lanthanide series: “s”-Δ-Eq-Ln4 and “c”Δ-Eq-Ln4, and “s”-Λ-Ax-Ln4 and “c”-Λ-Ax-Ln4 isomers (Figure 2.3.3).
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Figure 2.3.3. Ln3/4 NMR flowchart. High and low energy conformations are indicated for the isomers.

The presence of both side and corner isomers required that the peaks found in the
NMRs be identified, which were identified using variable temperature and twodimensional correlation spectroscopy experiments.
Variable Temperature Experiments
Variable temperature experiments were performed on the Yb4, Eu3, and Eu4 samples.
Since temperature and induced shifts are inversely proportional, it was expected, and
observed, that as the temperature increased the induced shifts decreased. This is best seen
in the axial protons of the chelates. Each chelate has 4 axially located protons on the
ethylene bridges between the nitrogen donor atoms in the macrocyclic ring. The axially
located protons are shifted based on their location to the metal. SAP isomer axial protons
are shifted further downfield than TSAP isomer axial protons. If one SAP isomer were
present in solution, there would be 4 highly shifted axial protons, and if two SAP isomers
are present in solution, there would be 8 highly shifted axial protons. The same is true for
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TSAP isomers. So in total, the Ln4 samples that contain all four isomers (“c”-Δ-Eq, “c”Λ-Ax, “s”-Δ-Eq, and “s”-Λ-Ax) should have 16 total axial protons in their 1H NMRs, 8
highly shifted SAP isomer axial protons and 8 less shifted TSAP isomer axial protons.
The Yb4 sample contained the “c”-Δ-Eq, “c”-Λ-Ax, “s”-Δ-Eq, and “s”-Λ-Ax isomers.
The variable temperature data (Figure 2.3.4) showed more than 4 signals for both the TSAP
and SAP axial protons, meaning that both the TSAP (“c”-Δ-Eq and “s”-Δ-Eq) and both the
SAP (“c”-Λ-Ax and “s”-Λ-Ax) isomers were present in solution. As the temperature was
increased, the “c”-Δ-Eq isomer and “c”-Λ-Ax isomer and the “s”-Δ-Eq isomer and “s”-ΛAx isomer that were in exchange through arm rotations moved toward each other, showing
that they were in exchange.

Figure 2.3.4. Yb4 variable temperature experimental data. The most shifted axial protons belong to the
SAP isomers “c”-Λ-Ax and “s”-Λ-Ax, and the less shifted axial protons belong to the TSAP isomers “c”Δ-Eq and “s”-Δ-Eq.

The Eu3 sample contained only the “c”-Λ-Eq and “s”-Λ-Eq isomers. More than 4
signals were observed as highly shifted axial protons and no signals were observed as
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TSAP axial protons (Figure 2.3.5). The two SAP isomers did not move toward each other
as temperature was increased. This was expected since the corner and side isomers are not
in exchange with one other. The rate of decreasing induced shift seemed similar between
the two isomers, with the “c”-Λ-Eq isomer rate decreasing slightly faster than the “s”-ΛEq isomer rate.

Figure 2.3.5. Eu3 variable temperature data. The axial protons belong to the SAP isomers “c”-Λ-Eq and
“s”-Λ-Eq.

The Eu4 sample contained the “c”-Δ-Eq, “c”-Λ-Ax, “s”-Δ-Eq, and “s”-Λ-Ax isomers.
The sample was comprised of predominately the “c”-Δ-Eq and “s”-Δ-Eq isomers but also
had a small amount of converted “c”-Λ-Ax or “s”-Λ-Ax isomer present. The TSAP axial
protons had more than 4 signals in the 1H NMRs taken, meaning that both the “c”-Δ-Eq
and “s”-Δ-Eq isomers were present (Figure 2.3.6).
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Figure 2.3.6. Eu4 variable temperature data. The axial protons visible on the right belong to the TSAP
isomers “c”-Δ-Eq and “s”-Δ-Eq.

In order to visualize the SAP isomer axial protons, the spectra needed to be zoomed in.
When the SAP axial protons were visualized, there were only 4 signals present, meaning
that the sample had either the “c”-Λ-Ax or the “s”-Λ-Ax isomer present, not both (Figure
2.3.7). As the temperature increased, the SAP isomer and the TSAP isomer it was in
exchange with moved closer together in the spectrum, slowing the rate of decreasing
induced shift in the related TSAP isomer. The four peaks representative of the SAP isomer
were present in a two by two pattern, or two sets of doublets. This pattern is the shifting
pattern for one of the regioisomers, either the “c”-Λ-Ax or the “s”-Λ-Ax isomer.
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Figure 2.3.7. Zoomed Eu4 variable temperature data. The axial protons visible belong to the SAP isomer,
either “c”-Λ-Ax or “s”-Λ-Ax.

The variable temperature experiments allowed for visualization of exchanging SAP and
TSAP isomers, but identification of the regioisomers wasn’t possible until the COSY
experiment was run.
COSY Experiments
The homonuclear correlation spectroscopy (COSY) experiment is used to identify spins
which are coupled to each other. In this experiment, a single isotope was looked at:
hydrogen. Specifically, the axial protons for the SAP and TSAP isomers were focused on
in order to identify side and corner regioisomers. The COSY spectra were obtained on Eu3
and Eu4 also offered insight into how the coordination cage distorts in these specific
chelates.
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Figure 2.3.8. COSY couplings. Top: The three couplings available to the axial proton on an unsubstituted
ethylene bridge. Center: The two couplings available to the axial proton on a corner substituted ethylene
bridge. Bottom: The two couplings available to the axial proton on a side substituted ethylene bridge.

An axial proton on an ethylene bridge has 3 other protons near it to couple to. The
strongest coupling that can occur is geminal coupling, which occurs between an axial
proton and an equatorial proton on the same carbon. The second strongest coupling that
can occur is vicinal coupling between the axial proton on one carbon and the axial proton
on the neighboring carbon (Figure 2.3.8). The weakest coupling that can occur is vicinal
coupling between an axial proton on one carbon and the equatorial proton on the
neighboring carbon. On an unsubstituted carbon, the axial proton will have 3 coupling
peaks on a COSY spectrum. If an ethylene bridge has a substitution on one of the carbons,
the substituent will reside in an equatorial position, which then leaves the axial proton with
2 other hydrogens near it to couple to. If the substituent is on the same carbon as the axial
proton, then there will be no geminal coupling in a COSY spectrum, only vicinal coupling
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between the 2 axial protons and vicinal coupling between the axial and neighboring
equatorial proton (Figure 2.3.8). If the substituent is on the neighboring carbon as the axial
proton, then there will be no vicinal coupling between the axial and neighboring equatorial
proton in a COSY spectrum, only geminal coupling and vicinal coupling between the 2
axial protons (Figure 2.3.8). Using this logic, the axial protons associated with the side and
corner regioisomers were identified.

Figure 2.3.9. Eu3/4 COSY spectra. The arrows pointing to each coupling are color coded to identify the
type of coupling. The resonances identified as corner or side have red crosses and orange double crosses
above them to indicate which resonance was analyzed, and the ending identity is labelled underneath the
resonance.

The first, and easiest, step in identifying protons next to a substitution was to count the
number of couplings associated with each peak. In the Eu3 sample (Figure 2.3.9), all but
two resonances had 3 coupling peaks. The two that didn’t have 3 coupling peaks had 2 and
by looking at the intensities of the coupling peaks, the second step, it was possible to
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determine which resonance belonged to the axial proton on the corner isomer and which
resonance belonged to the axial proton on the side isomer. The most shifted resonance with
2 coupling peaks, near 38 ppm, had a strong coupling peak and an intermediate coupling
peak, which meant that the axial proton was missing the weakest coupling, the axial proton
on one carbon coupling to the equatorial proton on the neighboring carbon. The most
shifted resonance was an axial proton on the carbon next to the substitution and, as such,
meant that the isomer was the corner regioisomer. Therefore, the most shifted axial proton
in the 1H NMRs taken belonged to the “c”-Λ-Eq isomer. The second resonance that had 2
coupling peaks, near 34 ppm, had what looked like two intermediate coupling peaks, which
meant that the axial proton was missing the strongest coupling, geminal coupling between
the axial proton and the equatorial proton on the same carbon. The second resonance with
2 coupling peaks was an axial proton on the carbon that had the substitution on it and, as
such, meant that the isomer was the side regioisomer. Therefore, the axial proton resonance
at 34 ppm belonged to the “s”-Λ-Eq isomer.
In the Eu4 sample (Figure 2.3.9), the SAP isomer only had 1 coupling peak per
resonance. Since 2 resonances were missing, it was concluded that the SAP coupling peaks
were the strongest coupling signals for those protons, meaning they were geminal
couplings. However, there were only 3 present in the spectrum, with the most shifted
resonance not having any coupling peaks. With the resonance missing the geminal coupling
between the axial proton and the equatorial proton on the same carbon, this resonance
belonged to the axial proton on the carbon with the substitution, or the side regioisomer.
Therefore, the SAP isomer present in the Eu4 sample was the “s”-Λ-Ax isomer. The TSAP
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isomer resonances near 16 ppm and 13 ppm were missing the strongest and weakest
couplings, respectively. Therefore, the resonance at 16 ppm belonged to the axial proton
on the carbon with the substitution, or the side regioisomer, and the resonance at 13 ppm
belonged to the axial proton on the carbon neighboring the substitution, or the corner
regioisomer. The TSAP isomer with the 16 ppm resonance was the “s”-Δ-Eq isomer and
the TSAP isomer with the 13 ppm resonance was the “c”- Δ-Eq isomer.
With Ln3, the proton located on the side carbon with the nitrobenzyl substituent had a
strong vicinal axs-eqc coupling, stronger than any of the other axs-eqc vicinal couplings
observed on the other ethylene bridges (Figure 2.3.9). This strong coupling means that the
macrocyclic ring was distorting the torsion angle (Φ) between the axs and eqc protons away
from the normal gauche conformation that should be observed, with the angle becoming
smaller than what is should have been (Figure 2.3.10). With Ln1, the coupling for the
proton located on the side carbon with the nitrobenzyl substituent was smaller, not larger
like in Ln3, which means that the angle in the Ln1 sample was being increased, not
decreased like in the Ln3 sample. The only difference between Ln3 and Ln1 is the amide
substituent; Ln3 contained the phenyl substituent (a hydrophobic group) and Ln1 contained
the carboxylic acid substituent (a hydrophilic group). Ln4 also had a distortion of the
macrocyclic ring away from the gauche conformation but in the opposite direction of Ln3.
The side regioisomer of Ln4 had weaker vicinal axs-eqc coupling, meaning that the angle
was larger than ideal, similar to the coupling found in the COSY of Ln1, not stronger with
a smaller angle like the Ln3 sample had (Figure 2.3.9). The electronic effects of the
substituents could be playing a role in the coordination cage structure but the
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stereochemical configuration of the delta substituent seems to be playing a bigger role in
affecting the direction of the distortion.

Figure 2.3.10. Substituted carbon gauche conformations. Left: Ideal gauche conformation. Right: Observed
gauche conformations in side and corner isomers based on COSY analysis.

In the case of the hydrophobic substituent, it is possible that the ring substituent was
aligning with the pseudo-equatorial phenyl derivative through pi bond interactions. This
suggested explanation also supports why only SAP isomers are present in the Eu3 samples.
The interaction between the ring substituent and the delta position substituent could help
to deter arm rotations which would interconvert between the SAP and TSAP isomers.
Differentiating Regioisomers
After identifying side and corner resonances in the COSY experiments, the variable
temperature experimental data was revisited and a shifting pattern for side and corner
regioisomers was identified. By tracing the axial protons and their movement as the
temperature was increased, patterns in the shifting of the protons became apparent (Figure
2.3.11). In the Eu4 sample, specifically, the “s”-Λ-Ax SAP isomer was in exchange with
the “s”-Δ-Eq TSAP isomer. Because of the exchange process, the resonances belonging to
the “s”-Δ-Eq isomer shifted at a different rate than the “c”-Δ-Eq resonances would. By

CHAPTER 2. STRUCTURAL MANIPULATION

80

observing which resonances in the variable temperature spectra did not shift upfield as
quickly, 4 resonances were identified as the axial protons of the side regioisomer, leaving
the 4 other resonances to belong to the corner regioisomer. The “s”-Λ-Ax and “s”-Δ-Eq
isomers had similar shifting patterns for their axial protons and the “c”-Δ-Eq isomer had a
different shifting pattern for its axial protons. The shifting pattern that appears to hold
across the series is a 2-2 shifting pattern for a side isomer and a 1-2-1 shifting pattern for a
corner isomer.

Figure 2.3.11. Eu3/4 variable temperature traces.

After identifying the shifting pattern of the side and corner regioisomers, determining
which resonances in a spectrum belonged to the side and corner isomers became fairly
obvious. Once regioisomers were identified, the areas under the resonances were measured
and ratios of Λ-Ax and Δ-Eq isomers could be determined for both the side and corner
regioisomers for all of the Ln4 samples (Figure 2.3.12). When the ratios were plotted across
the series, it was found that the transition from the Δ-Eq isomer to the Λ-Ax isomer occurs
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earlier in the series for the side regioisomer than it does for the corner regioisomer. The
side isomer begins to transition from TSAP to SAP isomer well before Gd3+, while the
corner isomer doesn’t appear to begin to transition until after Gd3+. This explains why only
the “s”-Λ-Ax isomer was observed in the Eu4 sample and why the “c”-Λ-Ax isomer was
not observed.

Figure 2.3.12. TSAP and SAP isomer ratio trends.

The trends indicate that the side isomer is better suited for smaller size lanthanide ions.
The shift from TSAP isomer in early lanthanides to SAP isomer in the later lanthanides
indicates that the SAP coordination cage is smaller than the TSAP isomer, and the trend
for the side isomer to make that shift sooner in the lanthanide series indicates that the side
coordination cage is likely smaller than the corner coordination cage. This would mean that
the smallest coordination cage available to the lanthanide ions is the “s”-Λ isomer, the
largest coordination cage available to the lanthanide ions is the “c”-Δ isomer, and the “s”Δ and “c”-Λ isomer coordination cages are in between the larger and smaller coordination
cages.
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CEST Experiments
CEST experiments were performed on several Ln3 and Ln4 isomers, including Pr3 and
Pr4, Nd3, Eu3 and Eu4, and Yb4 (Figure 2.3.13). Some CEST effect from bound water
was observed in all of the chelates run.

Figure 2.3.13. Ln3/4 CEST spectra. Top left: Pr3 (red). Top right: Pr4 (green). Bottom left: Nd3 (blue).
Bottom right: Yb4 (purple).

However, only Eu3 and Eu4 were extensively studies so that comparisons could be
made to the Eu1 and Eu2 CEST results that were previously obtained.
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Figure 2.3.14. Eu3 CEST spectra and omega plot.

In the Eu3 sample, both the “s”-Λ-Eq isomer and “c”-Λ-Eq isomer had CEST peaks
where the bound water was expected to be (Figure 2.3.14). The intensities of the peaks
increased with increasing B1 power (increasing pulse power: orange, purple, green, blue,
red), but the regioisomer that had the most intense peak changed as the power levels of the
pre-saturation pulse changed. The water proton exchange rates of the two isomers were
found to be very similar based first on the CEST peak widths and shapes and then
confirmed second with omega plots generated from the varying B1 CEST data collected
(Figure 2.3.14). The higher shifted peak represents the “c”-Λ-Eq-Eu3 isomer with a water
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residence lifetime of 3.15 ms and the lower shifted peak represents the “s”-Λ-Eq-Eu3
isomer with a water residence lifetime of 3.70 ms.

Figure 2.3.15. Eu4 CEST spectra.

The Eu4 data was more interesting with CEST peaks arising from the major TSAP
isomers (“s”/”c”-Δ-Eq-Eu4) and the minor SAP isomer (“s”-Λ-Ax-Eu4) present in solution
(Figure 2.3.15). Due to their fast water exchange kinetics, TSAP isomers do not usually
appear in CEST spectra. However, in the case of the “s”-Δ-Eq-Eu4 and “c”-Δ-Eq-Eu4
isomers, the water exchange kinetics are slow enough for the isomers to appear in these
spectra. The “s”-Λ-Ax-Eu4 isomer present in solution had an observed CEST peak and the
intensity of it increased as the pre-saturation pulse (B1) power was increased (increasing
pulse power: orange, purple, green, blue, red), which was expected. The “s”-Λ-Ax-Eu4
isomer made up only approximately 2% of the total chelate in solution for the Eu4 sample,
so the peak intensities were normalized with the respective chelate isomer concentrations
to give %CEST/mM values, which allowed the “s”-Λ-Eq-Eu3 and “c”-Λ-Eq-Eu3 isomers
and the “s”-Λ-Ax-Eu4 isomer to be compared (Table 2.3.1). The percent CEST for the “s”-
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Λ-Ax-Eu4 isomer was 47.1 %CEST/mM and the percent CEST for the “s”-Λ-Eq-Eu3 and
“c”-Λ-Eq-Eu3 isomers was 10.4 and 8.6 %CEST/mM, respectively, at 148 Hz, the lowest
B1 power level used. The “s”-Λ-Ax-Eu4 isomer had a greater percent CEST than either of
the “s”/“c”-Λ-Eq-Eu3 isomers.
Table 2.3.1. Eu3/4 SAP isomer %CEST values and τm values.

To get such a significant CEST signal from a minor isomer in solution means that the
“s”-Λ-Ax-Eu4 isomer is at least 4.5 times more efficient as a CEST agent than either of
the “s”/“c”-Λ-Eq-Eu3 isomers at the lowest B1 power level. This means that the “s”-Λ-AxEu4 isomer has slower water exchange than the “s”/“c”-Λ-Eq-Eu3 isomers, indicating that
the position of the amide substituent can affect the water exchange rate of the chelate,
especially when the substituent has an electronic effect associated with it.

CHAPTER 2. STRUCTURAL MANIPULATION

86

Figure 2.3.16. Eu4 omega plot.

When the omega plot for the “s”-Λ-Ax-Eu4 isomer was created (Figure 2.3.16), the
line produced was non-linear and did not give a single value for the water residence
lifetime. A wide range, 4.68 to 10.6 ms, was found instead and it was much slower than
the water residence lifetimes found for either of the “s”/“c”-Λ-Eq-Eu3 isomers. The nonlinear results of the omega plot were first thought to be an instrumental error. However,
upon further inspection, it was noted that the CEST peaks for the “s”-Λ-Ax-Eu4 isomer
were slightly asymmetrical, suggesting a second SAP isomer present in solution that did
not appear in any of the other NMR experiments performed. A second SAP isomer,
presumably the “c”-Λ-Ax-Eu4 isomer, would explain the non-linearity of the omega plot
and would be in exchange with the “c”-Δ-Eq-Eu4 isomer. The fact that the “c”-Λ-Ax-Eu4
isomer might show up in the CEST experiment but no other NMR experiment suggests that
it makes up less than the “s”-Λ-Ax-Eu4 isomer in solution. Despite its presumed low
concentration, it has a very strong CEST effect indicating that it has extremely slow water
exchange, slower than the “s”-Λ-Ax-Eu4 isomer. The limits of the water exchange rate
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range found from the two linear portions of the Eu4 omega plot could represent both
isomers’ water exchange rates, with the “s”-Λ-Ax isomer having a water exchange rate of
4.68 ms and the “c”-Λ-Ax isomer having a water exchange rate of 10.6 ms. The
asymmetric nature of the Ln4 SAP isomer CEST peaks is also seen in the Yb4 CEST
spectrum, where both the “s”-Λ-Ax and “c”-Λ-Ax isomers were observed in the 1H NMRs
taken (Figures 2.3.2 and 2.3.13). So the idea that the Eu4 sample contains both isomers is
not completely unbelievable.

Figure 2.3.17. Eu3/4 CEST flowchart. Found τm values are indicated. “τm = nm” means the τm value was
not measured.

These results suggest that the water proton exchange rates of the chelates are affected
by the chirality of the δ substituted methyl group, mainly because of the nature of the
substituent that is being moved in space. For the “s”/“c”-Λ-Eq-Eu3 isomers, the bulky
hydrophobic group was in a pseudo-equatorial position (Figure 2.3.17) and therefore had
little interaction with any water molecules attempting to access the water coordination site
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on the europium ion. However, with the “s”-Λ-Ax-Eu4 isomer, and possibly the “c”-ΛAx-Eu4 isomer, it is clear that there was a drastic slowing of the water exchange rate
suggesting that the bulky hydrophobic phenyl group was interacting more with the water
exchanging on and off of the chelate and could be explained by the group being in a pseudoaxial position (Figure 2.3.17) and creating a sort of hydrophobic tunnel that water has to
travel through in order to coordinate to the metal.
2.4.

Conclusions
Changing the amide substituent from a hydrophilic to a hydrophobic moiety enhanced

the CEST effect seen in the Eu3+ NB-DOTAM chelates. The identification of an extremely
effective CEST agent was complete, with the “s”-Λ-Ax isomer having a %CEST/mM over
4.5 times higher than the “c”-Λ-Eq and “s”-Λ-Eq isomers. The suggestion of the “c”-ΛAx isomer being present in solution and being detectable in CEST experiments is also
promising. Isolating each isomer and further studying the CEST effectiveness of each
isomer would be the next logical step for this research, which is possible with the
incorporation of an α position arm substitution added into the chelate structure and HPLC
purification.
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CHAPTER 3. ENCAPSULATION USING VESICLES
3.1.

Vesicle Characterization

Vesicle Formation, Size and Stability
Verifying the vesicle synthesis and characterizing the vesicles themselves was the first
step of this project. Of particular interest was making sure the systems could be controlled
experimentally and to know the volume of water associated with the inside and outside of
the vesicles.
A range of vesicle sizes were made, 50 nm, 80 nm, 100 nm, and 200 nm, and the lipid
compositions were 100% egg phosphatidylcholine (LAP, 60%) and 1:1 egg
phosphatidylcholine and cholesterol (LAP/C). The egg phosphatidylcholine lipid was 60%
pure with a variety of other lipids present, the exact composition of which was not
attainable from the vendor. The vesicles were made by extruding a solution of water (10
mL) and lipid at a concentration of 5 mg/mL through a polycarbonate membrane with pores
of the desired sizes and dynamic light scattering (DLS) was performed to see the mean
vesicle size of the sample. The sizes of the sample vesicles were monitored every day on
the same instrument over a week to see how stable the vesicles were (Figure 3.1.1). Their
mean sizes varied slightly over the week of monitoring, which may be an indication that
the vesicles were above their phase transition temperature. Phosphatidylcholine has a phase
transition temperature between -5°C and -15°C, so the vesicles were definitely in the fluid
phase at room temperature as opposed to being set into a solid gel phase below the phase
transition temperature. The 50 nm sized vesicles had smaller variation in size over the week
and the 200 nm sized vesicles had a larger variation over the week. The 50 and 80 nm

CHAPTER 3. ENCAPSULATION

90

extruded vesicles were larger than their intended sizes and the 200 nm extruded vesicles
were smaller than their intended size, while the 100 nm extruded vesicles were their
intended size. There was no trend in difference of size seen between the vesicles that
contained cholesterol and the vesicles that did not contain cholesterol.

Figure 3.1.1. Vesicle stability over 8 days.

It was observed during vesicle synthesis that when cholesterol was added into the lipid
mixture, the extrusion process through the polycarbonate membranes took significantly
longer to perform and there was loss of lipid out of solution found on the membranes when
the extrusion apparatus was taken apart for cleaning. Due to these observations, and the
observations that the cholesterol seemed to offer no extra stability over time or control of
vesicle size, it was decided that moving forward only lipid compositions consisting of the
100% egg phosphatidylcholine would be examined, without adding cholesterol.
Complex Addition and Dialysis Control
Once the stability of the vesicles had been gauged and control of the size of the vesicles
was achieved, the next step was encapsulating complex inside the vesicles, removing
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excess chelate from the outside of the vesicles, and making sure that the vesicle size did
not change from the dialysis process. Vesicles were made in buffer solutions containing
varying amounts of GdDTPA-2, extruded to the desired sizes, and then dialyzed to remove
any chelate from the outside of the vesicle while maintaining the desired size and shape of
the vesicles. Dialysis was carried out with buffer baths being changed out at various time
points to monitor whether or not the dialysis was working by looking at the T1 values of
the buffer baths. GdDTPA-2 is a T1 shortening agent. At the start of the dialysis process,
the T1 value of the buffer bath should be short because there should be
more

GdDTPA-2 that is being pulled into the buffer bath. As the dialysis continues,

the amount of GdDTPA-2 being pulled into the buffer bath should decrease as the
GdDTPA-2 is removed from outside of the vesicles and the T1 value should get longer as
time goes on.
The first dialysis monitored was on a 5 mM GdDTPA-2 100 nm vesicle sample and was
performed at 8 hour intervals (Figure 3.1.2). The T1 values obtained for the baths indicated
that the dialysis was essentially complete with all GdDTPA-2 removed from the outside of
the vesicles by 24 hours.
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Figure 3.1.2. Dialysis bath T1 values for 5 mM GdDTPA-2 100 nm LaPC vesicles.

A second 5 mM GdDTPA-2 100 nm vesicle synthesis and dialysis was performed, this
time with the dialysis buffer bath being changed every hour for 8 hours and then changed
one last time at 25 hours (Figure 3.1.3). The results showed the T1 value was short at first
and then it lengthened incrementally over the 8 hours that the baths were changed. The last
buffer bath change at 25.8 hours showed a value similar to that obtained at 23 hours in the
first dialysis bath monitoring experiment (1190 ms and 1178 ms, respectively).

Figure 3.1.3. Dialysis bath T1 values for 5 mM GdDTPA-2 100 nm LaPC vesicles, second attempt.
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Before and after the dialysis was performed, the size of the vesicles was also monitored.
If the osmolarity of the original buffer doesn’t match the osmolarity of the dialysis bath,
one of two things can happen: either the vesicles osmotically shrink or they osmotically
swell. Both consequences are undesirable because they each compromise the shape and
stability of the vesicles. Osmolarity is the concentration of a solution expressed as the total
number of solute particles per liter. In the case of the buffers being used for this project,
each buffer had 100 mOsm NaCl, 100 mOsm hepes buffer, and whatever concentration of
GdDTPA-2 was being tested (20, 15, 5, 4, 3, 2, or 1 mM GdDTPA-2). Osmotic shrinking
occurs when the osmolarity of the solution on the inside of the vesicle is smaller than the
osmolarity of the solution on the outside of the vesicle (Figure 3.1.4).

Figure 3.1.4. Osmotic shrinking mechanism.

The gradient of osmolarity that is created across the phospholipid bilayer by the
different osmolarities causes water to move from the inside of the vesicle to the outside of
the vesicle to equalize the osmolarities. Osmotic swelling occurs when the osmolarity of
the solution on the outside of the vesicle is smaller than the osmolarity of the inside of the
vesicle and water moves from the outside of the vesicle to the inside of the vesicle.
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Figure 3.1.5. Osmotic swelling mechanism.

When vesicles shrink, the shape of the vesicle distorts from spherical to more of an egg
shape. The distortion affects the water exchange efficacy of the vesicle and slows the water
exchange rate because the lipids are stressed and pushed closer together as the curvature of
the bilayer is changed. When vesicles swell, the phospholipid bilayer gets thinned out and
stretched with the efficacy of the lipid packing being compromised. This leads to an
increase in the water exchange kinetics across the lipid membrane.

Figure 3.1.6. Mean vesicular diameter before and after dialization.
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Both of the aforementioned 5mM GdDTPA-2 100 nm samples shrank during dialysis.
The change in size observed was considered enough to distort the shape of the vesicle,
making it less spherical and more oval in shape. This distortion was expected to have an
effect on the water exchange rate of the vesicles. In fact, several attempts were made to get
the osmolality correct during dialysis so vesicles were not shrinking or swelling; however,
despite redoing calculations, and making changes to the concentrations of the salts added
to the buffer, all samples that were made and dialyzed shrank or swelled to some degree.
The only sample that didn’t shrink or swell was the 20 mM GdDTPA-2 samples (Figure
3.1.6). A suspended dialysis was also tried to see if concentrating the sample was possible,
but it didn’t afford any more concentrated of a sample and it also shrank the vesicles.
3.2.

T1 Analysis of Vesicle Systems
T1 values are measured by using an inversion recovery experiment. In this experiment,

the spins of the system are pulsed 180° from the z-axis to the –z-axis, and the sample is
allowed to return to the z-axis for some time, τ. After time τ, the spins are pulsed 90° into
the x-y plane where the signal intensity is measured. This allows for a data point to be
placed for that length of time τ. The next time the spins are pulsed into the –z-axis, the time
τ is lengthened, and the spins are allowed to relax a little bit more to the z-axis, meaning
that the intensity of the signal will be less than the previous τ time when the spins are pulsed
into the x-y plane. As some point, the time τ that the spins are allowed to return to
equilibrium will allow the net sum of the spins to be in the z-axis before being pulsed into
the x-y plane. When this happens, the amount of signal read in the x-y plane will begin to
grow again until the spins are completely allowed to relax back to the z-axis with a longer
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time τ. The amount of time that is required for the spins to completely relax back to the zaxis and the rate of return during time τ depends on the T1 value of the sample (Figure
3.2.1). The VD (variable delay) list controls the values of τ, and generally changes from
sample to sample based on the T1 value. If the sample has a long T1 and a VD list for a
short T1 is used with a short relaxation delay, scattering is possible since the sample doesn’t
have adequate time to relax back to equilibrium before the next inversion pulse is applied
and the experiment will likely be cut off before the sample has time to fully relax with
longer τ values.

Figure 3.2.1. Various concentrated samples of GdDTPA-2 showing the changing rate of T1 relaxation.

20 MHz T1 Data
Several attempts were made to probe the exchange kinetics across the phospholipid
bilayer and to assess the ratio of internal and external water in the system using T1 recovery
NMR experiments. Both the dialyzed and non-dialyzed samples were run at 20 MHz and
25°C for T1 values. With the non-dialyzed samples, it was expected that one T1 value would
be obtained (mono-exponential T1 systems) due to the fact that GdDTPA-2 was both inside
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and outside the vesicles and therefore the T1 value on the inside and outside would be the
same. The expected T1 values for the non-dialyzed samples were calculated using the
concentrations of GdDTPA-2 for each sample. The dialyzed samples were expected to have
two T1 values (bi-exponential T1 systems), one for the inside of the vesicle where
GdDTPA-2 was still present and one for the outside of the vesicle where there was no longer
any GdDTPA-2 after dialysis. The values of the two pools, the inside and the outside of the
vesicles, depended on the exchange rate across the bilayer. If exchange was slow on the
NMR timescale, the two compartments would have very different values; the inside of the
vesicle would have a T1 close to that of the undialyzed samples and the outside of the
vesicles would have a T1 value close to that of water. If exchange was fast on the NMR
timescale, the two compartments would be considered well mixed and the values for the
inside and outside of the vesicles would be close to the same. If exchange was somewhere
in between slow and fast, then the two T1 values found would have some other T1 values
representative of some mixing, not all or none.
When running samples on the 20 MHz minispec at OHSU, the instrument fits the data
and gives a T1 value for each sample. It can be controlled whether or not the program tries
to fit the data to a monoexponential or a biexponential fitting, and the delay values used
for the inversion recovery experiment can be changed. However, there is not actual
manipulation of the data done by the researcher. Everything is done on the instrument by
the program.
T1 values were not realistic, with one always far too long or too short to be a real T1.
One T1 value was expected to be obtained for the non-dialyzed samples and two T1 values
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for the dialyzed samples. What was observed was that as the concentration of the
GdDTPA-2 decreased inside the vesicles, the T1 value obtained for the non-dialyzed
samples lengthened. Also observed was the fact that each sample had the T1 values go from
short to long in the undialyzed to dialyzed samples, respectively. This data shows that the
dialyzation to remove external GdDTPA-2 was successful (Figure 3.2.2). However, the
dialyzed samples had no clear trend.

Figure 3.2.2. T1 values of vesicle containing GdDTPA-2 samples before and after dialysis.

Water’s expected T1 value is at least a couple of seconds. The exact value is unknown,
and attempting to run just water on the spectrometer proved to be futile. The 20 mM
GdDTPA-2 vesicles appeared to have very rapid exchange of water across the phospholipid
bilayer of the vesicles because the T1 value of the dialyzed sample is very short compared
to what would be expected for water. This means that water from the inside of the vesicle,
which has a shortened T1 value due to the GdDTPA-2 being present, was leaving the vesicle
and exchanging with the bulk water outside of the vesicle quickly enough to have an
observed shortening of the T1 value of the outside of the vesicle. As the concentration of
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GdDTPA-2 was decreased inside the vesicles, the shortening of the outside water should
become less drastic, with the 5 and 1 mM GdDTPA-2 vesicles having longer T1 values for
the dialyzed samples than the 20 mM GdDTPA-2 vesicles. However, with the 5 mM and 1
mM GdDTPA-2 vesicles, the expected lengthening of T1 values was the opposite of what
was observed. The T1 values for the 1 mM vesicles were shorter, not longer.
There were a couple of explanations for this. One was that the 5 mM GdDTPA-2
vesicles were 100 nm vesicles and the 1 mM GdDTPA-2 vesicles were 200 nm vesicles.
With different sizes of vesicles, it is hypothesized that vesicles will appear to have different
water exchange kinetics. Since the vesicles were different sizes, comparing them directly
could not actually be done. Keeping one of the parameters (either concentration of chelate
or size of vesicle) constant could have helped to explain the trend that was seen. Another
explanation as to why the T1 values were reversed from what was expected was that the
lipid concentration used when the vesicle batches were made were different. The 5 mM
GdDTPA-2 vesicles were synthesized with a lipid concentration of 5 mg/mL. The 1 mM
GdDTPA-2 vesicles were synthesized with a lipid concentration of 20 mg/mL. The change
in lipid concentration when the vesicles were made could have affected the permeability
of the vesicles. However, it would make sense that a more concentrated lipid bilayer would
be less permeable to water and therefore would have a longer T1 value for the dialyzed
sample. This is again opposite of what was observed.
Another problem noted with the data collected on the 20 MHz spectrometer was that
the values found for one sample could change from one run to another. So if one sample
was run two times in a row, the resulting data could differ drastically. In one run, the sample
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being run would be monoexponential and in a second run the sample would be
biexponential. If the monoexponential fit was turned on, generally one T1 value was given.
However, if the biexponential fit was turned on, two T1 values were not always given. And
if a sample was supposed to be monoexponential, like undialyzed samples, the program
would give two T1 values as if it was biexponential. Sometimes T1 values would differ by
hundreds of ms. Since the results that were obtained were not reproducible on the 20 MHz
instrument, data collection was moved to the 600 MHz instrument on PSU’s campus.
600 MHz T1 Data
When data collection was moved to the 600 MHz, another change to sample prep was
made. Since keeping vesicles from shrinking and swelling after dialysis was proving to be
difficult, it was suggested that the chelate being used could be put on the outside of the
vesicle instead of the inside of the vesicle. This alleviated the need to dialyze the samples
and presumably would keep the vesicles from shrinking or swelling. For these experiments,
the samples were made using a buffer with only 100 mOsm NaCl and 100 mOsm hepes
buffer and no complex. Once the vesicles had been extruded, then complex was added to
the samples. This method allowed for several different samples to be made at once instead
of one sample being made each time the extruder was used. For these samples, 10 (or at
least 5) mL samples were extruded, ensuring that each different concentration sample
contained the same concentration of lipid and were the same sizes. The large sample of
formed vesicles were split into 1 mL samples and the desired amounts of GdDTPA-2 were
added to each sample in the smallest amount of stock buffer to make a range of
concentrated samples (15, 5, 4, 3, 2, or 1 mM GdDTPA-2). The stock buffer contained 1 M
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GdDTPA-2, 100 mOsm NaCl, and 100 mOsm hepes buffer. The amounts added to the
solutions were on the order of μL.
The experiments on the 600 MHz make up the majority of the T1 experiments run.
While the LAP vesicles were primarily studied, some parameters were changed (see table).
Lipid composition was changed to incorporate cholesterol and also changed completely to
DPPC, concentration of the lipid used was changed from 5 mg/mL to 25 mg/mL, the vesicle
samples were concentrated down after formation using centrifugation, and the formation
of the vesicles was also altered to include freeze-thawing (FT) cycles before the extrusion
process. The VD list used in the collection of the data was also changed. Generally, a
concentration specific VD list was used, but including a concentration independent VD list
was used in hopes that the longer T1 value would be better represented in the data collected.
Collecting data on the 600 MHz instrument required that the data be worked up manually
and be fitted manually. Two different methodologies each were used to analyze the data
and fit the data.
Processing and Fitting the 600 MHz Data
The original (O) processing method involved analyzing the data using the T1 analysis
method on the Bruker program. In this method, an integration was made to the phased last
spectrum taken (the one with the most signal) to indicate to the program what peak to look
at to pick data points. Then the program pulls the data (tau value, ppm associated with the
peak measured, integral of that peak, and the intensity value of that peak) and creates a
recovery curve of data, which was then exported into a text file and imported into an excel
sheet. From there, the data was manipulated in excel.
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All of the parameter changes are presented in Table 3.2.1. In the following graphs, the
original (O) method is represented by blue bars and the professional (P) method is
represented by green bars. Solid bars are representative of monoexponential (M) fitting
results and open bars are representative of biexponential (B) fitting results. Bars filled
with lines represent T1 values that had population size values of 0. Black dashed lines are
representative of a calculated T1 value for water, which was found from graphing the
concentration of free GdDTPA-2 solutions versus the relaxivity of each solution and red
dotted lines represent the T1 values found from those concentrations of GdDTPA-2
solutions. Purple dotted lines, which are only found on 15 mM GdDTPA-2 graphs, are a
calculated value for the expected T1 value. The dashed and dotted lines are included in the
graphs to help give ideas of where expected values might have been.

Table 3.2.1. Changing parameters for comparisons and better data fitting.
Parameter
Changing

Base

Change Made

Expected Change in Water
Exchange Rate

LaPC Only

add cholesterol
use DPPC
use DPPC + add
cholesterol

slow water exchange across
membrane

2 distinct species: 1 T1 value consistent
with the GdDTPA concentration and 1 T1 value
consistent with water

Starting Lipid
Composition

5 mg/mL

increase to 25
mg/mL

slow water exchange across
membrane

2 distinct species: 1 T1 value consistent
with the GdDTPA concentration and 1 T1 value
consistent with water

Method of
Vesicle Formation

Film
Hydration and
Extrusion

Lipid
Composition

Film Hydration,
Repeated Freeze-Thaw
Cycles, and Extrusion

Vesicle Size

200 nm

50 nm, 80 nm,
100 nm, 1 μm

Concentration
of Vesicles

5 mg/mL

increase to 24, 33,
and 215 mg/mL

Data
Collection Method
Data Analysis
Method

Concentration
Dependent
VDList
Original (O)
Method

Concentration
Independent VDList
Professional (P)
Method

should not change water
exchange rates; should ensure that
the system is only 2 site exchange
increase exchange rate in the
smaller vesicles; decrease
exchange rate in the larger vesicles
should not change water
exchange rates; should make the
volume ratio H2Oi:H2Oe more
equal
should not change water
exchange rates
should not change water
exchange rates; should make fitting
data easier and should produce
more accurate results

Expected Change on T1 Values

more reliable biexponential fitting result
larger vesicles exhibiting 2 distinct species;
smaller vesicles not exhibiting 2 distinct
more reliable biexponential fitting result
with equal contributions to the T1 values
accurate T1 values should be obtained since
all of the signal (primarily that of the species
with the longer T1) is collected
accurate T1 values should be obtained since
the peaks used in analysis are better phased and
integral instead of peak intensity is used
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Lipid Composition Comparison
The first study that was performed on the 600 MHz was to look at how the composition
of the lipid changed the exchange rates. Initially, only phosphatidylcholine (LaPC) was
used in the preparation of the vesicles. Cholesterol was eventually added in a 1:1 molar
ratio (LaPC + C). The beginning concentration of the lipid was either 5 mg/mL or 25
mg/mL, and the vesicles were extruded at 200 nm or not at all (Non Extruded).
All of the samples (Figure 3.2.3) gave monoexponential (M) fittings with T1 values
around the free 5 mM GdDTPA-2 T1 value for both the original (O) and the professional
(P) analysis method. In the original analysis method, the biexponential (B) fittings, except
for the Non Extruded LaPC at 25.06 mg/mL initial lipid concentration, gave one T1 value
near the free 5 mM GdDTPA-2 T1 value and one T1 value that was above 200 s. The T1
values that were above 200 s all had population sizes of 0 associated with them. This means
that the value is erroneous and not present in the sample; it is simply just a value that the
fitting put in as a place holder. In the professional analysis method, the biexponential
fittings all gave two T1 values close to the free GdDTPA-2 T1 value and the population sizes
were between 80-70% and 20-30%. No real improvement was made by adding cholesterol,
increasing the amount of starting lipid, or even by extruding the samples. These data
suggest that the exchange rate across the phospholipid bilayer is fast on the NMR timescale
and that the two pools of water in the system (the external with GdDTPA-2 and the internal
without GdDTPA-2) are well mixed.
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Figure 3.2.3. 5 mM GdDTPA-2 vesicle systems.

DPPC was also looked into as an alternative lipid, however, proper formation of the
vesicles proved to be difficult. While the LaPC lipid went into suspension in the buffer
solutions well, DPPC alone did not go into solution easily, required heating above the
transition temperature for the lipid (41°C), and required that the sample be kept above that
temperature during the extrusion process. This was easily achieved since the extruder in
lab has a water-jacketed barrel where the sample is kept and extruded. Even with heating
and staying above the transition temperature, it was still difficult to synthesize the DPPC
vesicles due to the extrusion process taking an abnormally long time to complete. Generally
the extrusion process is quick, with only the first pass through the filters being slow. The
DPPC vesicles were difficult to extrude during all 10 passes through the filters, with one
sample taking over 3 hours to extrude. DLS after the extrusion of the DPPC only vesicles
showed bimodal distributions in a lot of the samples prepared (Figure 3.2.4), and cleaning
the extruder after the extrusion always showed signs of major lipid loss on the filter.
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Figure 3.2.4. 5 mg/mL DPPC prepared at 43°C, before and after extrusion at 50 and 200 nm.

Adding cholesterol in with DPPC made the extrusion process of the synthesis easier,
and did not require heating before and during the extrusion process (Figure 3.2.5). The size
distributions of the DPPC + C vesicles were monomodal and showed homogenous sizes in
the sample.

Figure 3.2.5. 5 mg/mL DPPC+C prepared at room temperature, before and after extrusion at 50 and 200
nm.
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However, despite efforts to keep the sample above the transition temperature and
adding cholesterol into the vesicle mix, the vesicles were not stable since lipid was visibly
sinking in the sample after extrusion. What this means is that the lipid was leaving the
suspension and collecting at the bottom of the vials the samples were kept in. The vesicles
made with DPPC were not analyzed by T1 analysis because the lipid concentration, the size
of the vesicles, and the stability of the vesicles could not be guaranteed.
Vesicle Size Comparisons
Lipid size was chosen based on the size of the polycarbonate pore filters bought for the
extruder. The sizes used for the 600 MHz experiments were 50 nm, 200 nm, and 1 μm.
Different sized vesicles were made for the 0, 1, 2, 3, 4, and 5 mM GdDTPA-2 vesicles. It
was expected that the exchange rate of the vesicles would vary with changing the vesicle
size. Typically, the larger the vesicle is the slower the exchange rate across the
phospholipid bilayer is, and the smaller the vesicle is the faster the exchange rate is.236
However, no apparent trend can be seen when changing the size of the vesicles.
Here, all of the samples gave monoexponential fittings with T1 values around the free
GdDTPA-2 T1 value for both the original and professional analysis method (Figure 3.2.6).
In the original analysis method, the biexponential fittings, except for the 4
mM

GdDTPA-2 sample, gave one T1 value near the free GdDTPA-2 T1 value and one T1

value that was above 200 s. The T1 values that were above 200 s all had population sizes
of 0 associated with them. In the professional analysis method, the biexponential fittings
all gave two T1 values close to the free GdDTPA-2 T1 value and the population sizes were
between 80-70% and 20-30%. This data suggests that the exchange rate across the
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phospholipid bilayer is fast on the NMR timescale and that the two pools of water in the
system are well mixed and that changing size of the vesicles does not change the observed
T1 values. The 0 mM GdDTPA-2 sample provided some interesting data, and does so
throughout all of the comparisons. In this case, the monoexponential fittings for both
analyses, and the professional method biexponential fittings gave T1 values that were very
low. It was calculated that the T1 of water would be around 3.8 s on the 600 MHz, but the
values given by the monoexponential and the professional analysis method biexponential
fittings were all well under 500 ms. The original analysis method biexponential fitting gave
one T1 value closer to the calculated water T1 and one value over 200 s. The biexponential
T1s that were over 200 s had a population size of 0.
Vesicle Concentration Comparison
The samples in this comparison were 200 nm LaPC vesicles that started with a
concentration of 5 mg/mL starting lipid. The vesicle samples were centrifuged down using
centrifugal filter units. The sample to be concentrated was placed into the centrifugal filter
unit, placed into a centrifuge at 4°C, and spun down until the sample size was small, which
typically took between 30 minutes and 4 hours depending on the amount of starting volume
and how concentrated the desired sample was. The concentrated samples then had
GdDTPA-2 added to the samples for T1 analysis. The samples tested had concentrations
from 0 to 5 mM GdDTPA-2, and 15 mM GdDTPA-2.
Concentrating the samples seemed to make a difference most with the original analysis
biexponential fitting results (Figures 3.2.7 and 3.2.8). The monoexponential fittings for
both analysis methods were similar to the free GdDTPA-2 T1 values, and the professional
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analysis method biexponential fittings gave T1 values that were still close to the free
GdDTPA-2 T1 values, and those T1 values had populations of 80-70% and 20-30%. The
original analysis method biexponential fitting results generally had one T1 value near the
free GdDTPA-2 and the second T1 value was either over 200 s or below 5 s. The samples
that were not concentrated down or just barely concentrated down had T1 values above 200
s, and the samples that were concentrated the most had T1 values below 5 s. Concentrating
the samples also changed the population sizes, but not following a trend. The most
concentrated samples had a second biexponential T1 value below 5 s that also had a
population value that was not 0. However, the population sizes were much less than those
achieved with the professional analysis method.
The 0 mM GdDTPA-2 sample had T1 values close to the calculated T1 value for water,
and seemed to benefit most from the concentration of the samples. However, there should
have been no benefit since this sample should only be monoexponential with no
GdDTPA-2 anywhere in the sample. While the T1 values obtained seemed to move in the
right direction with concentration, they still were not where they were expected.
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Figure 3.2.7. Vesicle concentration comparison T1 values for 0-5 mM GdDTPA-2 samples.
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Figure 3.2.8. Vesicle concentration comparison T1 values for 15 mM GdDTPA-2 samples

Vesicle Formation Comparison
The original vesical formation technique employed just extrusion. This methodology
was supposed to form ULVs while making the size distribution homogenous within the
sample. In order to make sure the ULVs were being made, a freeze-thaw cycle was added
to the vesicle synthesis. The freeze thaw cycles involved flash freezing the vesicles in a
liquid nitrogen bath and then thawing them out in a heated water bath. This method is
supposed to produce only ULVs and not MLVs. The idea here is that the frozen water
breaks up the smaller vesicles inside the larger vesicles and forces the lipid from the smaller
vesicles to join the larger vesicle upon thawing.
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Figure 3.2.9. Formation method comparison T1 values for 0-5 mM GdDTPA-2 samples.
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Figure 3.2.10. Formation method comparison T1 values for 15 mM GdDTPA-2 samples.

In the normal vesicle formation, the 6 T1 values collected follow the trends already
discussed (Figures 3.2.9 and 3.2.10). With the exception of the 0 mM GdDTPA-2 sample,
the monoexponential fittings and the professional analysis method biexponential fittings
were near the free GdDTPA-2 T1 value, and the original analysis method biexponential
fittings had one T1 value near the free or calculated GdDTPA-2 T1 value and the other T1
value was over 200 s. However, the results from changing the vesicle formation have a
trend unlike any of the other data comparisons. The T1 values in all of the original 200 nm
LaPC vesicles with 5.69 or 5.51 mg/mL initial concentration of lipid, except for the 0 and
1 mM GdDTPA-2 samples, are all larger than those found for the 200 nm FT LaPC vesicles
with 5.01 mg/mL initial concentration of lipid. The values follow the same trend as the
original vesicles, but with smaller T1 values given from the fittings. The reason for this is
unknown. This could be a result of there only being one compartment in each vesicle.

CHAPTER 3. ENCAPSULATION
1

1.7841

1.7595

0.9

0.9

0.8

0.8

0.7

0.7
T1 Value, s

T1 Value, s

1

115

0.6
0.5
0.4

0.2

0.1

0.1
0
200 nm LaPC
(215.77
mg/mL)

1

200 nm LaPC
(215.77
mg/mL)
VDList

2 mM GdDTPA
LaPC Vesicles

215.27

65.37

1

203.81

0.9

T1 Value, s

0.4

1.6146

201.88

0.6
0.5
0.4

0.3

0.3

0.2

0.2

0.1

0.1

0

0
200 nm
LaPC
(215.77
mg/mL)

200 nm
LaPC
(215.77
mg/mL)
VDList

4.8704

200 nm
FT LaPC
(5.01
mg/mL)

8.855

200 nm
FT LaPC
(5.01
mg/mL)
VDList

1.958

4 mM GdDTPA
LaPC Vesicles
0.2

202.29

0.18

0.4

0.16

0.35

0.14
T1 Value, s

0.45

0.3
0.25
0.2

200 nm
LaPC
(215.77
mg/mL)
VDList

200 nm
FT LaPC
(5.01
mg/mL)

200 nm
FT LaPC
(5.01
mg/mL)
VDList

202.62
2.355

0.2933

0.2933

0.1
0.08
0.06

0.1

0.04

0.05

0.02

0

200 nm
LaPC
(215.77
mg/mL)

0.12

0.15

5 mM GdDTPA
LaPC Vesicles

12.923

0.7

0.5

0.5

2.1649

200 nm LaPC
(215.77
mg/mL)
VDList

0.8
0.7193

0.6

3 mM GdDTPA
LaPC Vesicles

200 nm LaPC
(215.77
mg/mL)

0.9

0.8
T1 Value, s

0.4

0.2

0

T1 Value, s

0.5

0.3

0.7

1.2

0.6

0.3

1 mM GdDTPA
LaPC Vesicles

2.215

0.0366

0
200 nm
LaPC
(215.77
mg/mL)

200 nm
LaPC
(215.77
mg/mL)
VDList

200 nm
FT LaPC
(5.01
mg/mL)

200 nm
FT LaPC
(5.01
mg/mL)
VDList

15 mM GdDTPA
LaPC Vesicles

200 nm 200 nm 200 nm
LaPC
LaPC FT LaPC
(215.77 (215.77
(5.01
mg/mL) mg/mL) mg/mL)
VDList

200 nm
FT LaPC
(5.01
mg/mL)
VDList

Figure 3.2.11. Data collection comparison T1 values for 1-5 and 15 mM GdDTPA-2 samples.
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Previously, encapsulated GdDTPA-2 was found to have a lower T1 value than free
GdDTPA-2 237,238, and it was suggested that this was due to a decrease in the exchange rate
between bulk water and the entrapped GdDPTA-2. In this case, the GdDTPA-2 is on the
outside of the vesicle, not on the inside and encapsulated, but the result should still be the
same since the chelate isn’t seeing all of the water in the system and therefore the relaxivity
is limited and lower than when the chelate isn’t around vesicles, or compartments.
However, it has been shown previously that there is fast exchange kinetics
when GdDTPA-2 is in the presence of whole blood and frog heart tissue and that T1 values
do not suffer a decrease in intensity239. The variable reports from previous studies make
knowing what to expect difficult.
Data Collection Comparison
The original samples were run with their respective concentration dependent VD lists,
and samples labelled with “VD List” in the name were also run with a concentration
independent VD list (see Chapter 4 for more information). No real trends were discernable
in the data collection analysis (Figure 3.2.11). This comparison seems to be the one with
the least amount of a trend available with the data collected. Including all of the signal in
the data collection does not seem to make the biexponential nature of the system more
readily apparent. The 15 mM GdDTPA-2 sample appeared to have a change in the
professional analysis method, but other than that, no trends were observed.
Finding the Encapsulated Volume of 100 nm Vesicles
Shift reagent experiments had previously been attempted to find the encapsulated
volume of vesicle batches. However, the encapsulated shift reagent was never visible,
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presumably because of the buffer showing in 1H NMRs. Even with the buffer removed
from the samples and the concentration of the shift reagent increased, the volume with the
shift reagent, whether inside or outside of the vesicles, was never visible on the 1H NMRs
taken. Therefore, geometry was used to estimate the amount of encapsulated water in the
vesicle systems.
Given that the vesicle is a 100 nm vesicle, the external diameter is 100 nm and external
radius is 50 nm. If the lipid wall thickness is 5 nm, then the internal diameter is 90 nm and
the internal radius is 45 nm. Both the internal area of the vesicle and the external area of
the vesicle are given by the following equation:
: = 4=# >
Where A is the area and r is radius. Therefore, the internal area of the vesicle is 25,446.9
nm2 and the external area of the vesicle is 31,415.93 nm2. If a choline head group area is
0.70 nm2/lipid head, then the number of head groups on the inside of the vesicle is
36,352.715 and the number of head groups on the outside of the vesicle is 44,879.895. If
those two values are added together, the total number of head groups in one vesicle, and
therefore the number of lipid molecules in one vesicle, is 81,232.610. Rounding this
number up to a whole value gives a total number of 81,233 lipids required to make up one
vesicle.
Since the general concentration of lipid used was 5 mg/mL, this gives a total of 0.05 g
of lipid in a 10 mL sample. Using the average molecular weight of LaPC (768 g/mol), the
number of moles of LaPC in a 10 mL 5 mg/mL sample is 6.5x10-5 moles. Using Avogadro’s
number, the number of lipids becomes 3.92x1019. Dividing this value by the number of
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lipids in one vesicle give the number of vesicles present in this specific sample, which is
4.826x1014 vesicles. Multiplying the number of vesicles in a sample by the internal volume
of a vesicle gives the total internal volume in one sample, which is given by the following
equation:
?=

4 A
=#
3

Where V is the volume and r is the radius. The internal volume of a 100 nm vesicle is
1.8437x1020 nm3. Converted, this value comes out to 0.18437 mL of internal volume per
every 10 mL total volume of 5 mg/mL 100 nm vesicle sample.
In order for the T1 analysis to work, at least 10% of the signal should be internal, and
in the present system, only 1.8% of the total volume is encapsulated right now. Even with
concentrating down the samples to decrease the external volume and increase the ratio of
encapsulated volume, the samples still aren’t concentrated enough, and there is no
guarantee that the samples that are concentrated down aren’t destroying the vesicles at the
same time. Without imaging the vesicles, there is no way to know whether or not the
technique of concentrating samples is destructive.
3.3.

CEST Analysis of Vesicle Systems

Preliminary Samples
A CEST response can be measured for a sample with 3-4% signal, therefore the
analysis method was changed from a T1 analysis to a CEST analysis. In this technique, the
vesicles were synthesized in the presence of 150 mM TmEDTA-1 and 150 mM
TmDTPA-2. The vesicles formed were either LaPC only or LaPC and cholesterol and the
samples were run at 25°C and 5°C. If exchange across the membrane were slow enough, a
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CEST signal would appear at the same frequency as the shifted protons. If exchange were
too fast across the membrane, no CEST signal would be observed.

Figure 3.3.1. Preliminary CEST spectra on vesicle samples. Top: 150 mM TmEDTA-1 samples. Bottom:
150 mM TmDTPA-2 samples. Green lines represent LaPC + C samples. Yellow lines represent LaPC only
vesicles. Solid lines represent room temperature experiments. Dashed lines represent low temperature
experiments.

The TmDTPA-2 samples had no CEST signal appear and the TmEDTA-1 LaPC vesicles
had no CEST signal; however, the TmEDTA-1 LaPC and cholesterol vesicles had
asymmetry in their spectrum, associated with CEST signal (Figure 3.3.1). These were
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preliminary data collected at low concentrations of shift reagent, so further experimentation
was done in a more thorough study, including control compounds.
Controlled Samples
Samples of 300 mM TmEDTA-1, TmDTPA-2, YEDTA-1, and YDTPA-2 were prepared
as buffer solutions for vesicle formation. Vesicles were formed for the TmDTPA-2 and
YDTPA-2 samples, but vesicles were not able to form using the TmEDTA-1 and YEDTA-1
samples. This was likely due to the fact that the EDTA being used was old and not fully
dry, leading to an uncertainty in the true amount of EDTA being added and resulting in
free Ln3+ ions being present in the solutions. Free Ln3+ ions make the formation of vesicles
difficult by coordinating with the polar head groups of the lipids. Therefore, only the 300
mM TmDTPA-2 and YDTPA-2 samples are presented. In order to know where to look in
the collected spectra, and shift experiment was performed where 2 M TmDTPA-2 was
diluted down in steps and 1H NMR spectra were run to see where the shifted protons of the
encapsulated water would occur (Figure 3.3.2). The YDTPA-2 chelate is not a shift reagent,
so no 1H NMR shift experiments were performed for it. The YDTPA-2 samples serve as
controls for the TmDTPA-2 samples since the YDTPA-2 chelate will be similar in its
coordination chemistry and geometry to the TmDTPA-2 chelate but will not have two
chemically different pools of water like the TmDTPA-2 samples will have.
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Figure 3.3.2. TmDTPA-2 concentration shift dependence experiment.

The shifting ability of the 150 mM TmDTPA-2 for the first experiments at 150 mM is
marked by a red x, and the shifting ability of the 300 mM TmDTPA-2 for the following
experiments is marked by a red square (Figure 3.3.2). In the 150 mM TmDTPA-2 samples,
the shifted CEST peak should have been around 11 ppm, while in the 300 mM TmDTPA2

samples, the shifted CEST peak should have been around 20 ppm. The TmDTPA-2 and

YDTPA-2 vesicle samples were run at varying pulse power levels (PL) in order to assess
how the CEST signal would change with power. If the %CEST signal changed with the
pulse power then it would be considered a true CEST signal and not an artifact from the
sample or instrument. On the 600 MHz spectrometer, as the pulse power level number
increases, the actual pulse power decreases, and vice versa. Therefore, a pulse power level
(PL) of 30 is actually a lower pulse power level than 12.
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Figure 3.3.3. 300 mM TmDTPA-2 200 nm LaPC vesicle CEST spectra.

Figure 3.3.4. 300 mM YDTPA-2 200 nm LaPC vesicle CEST spectra.

The 300 mM TmDTPA-2 LaPC only vesicles did not produce any CEST signal, other
than slight asymmetry and broadened spectra (Figure 3.3.3). The 300 mM YDTPA-2 LaPC
only vesicles had narrow water saturation peaks (Figure 3.3.4), which was expected since
the water inside and outside of the vesicles was chemically equivalent. The broadened
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nature of the TmDPTA-2 sample could be an indication of multiple chemically
nonequivalent environments, which is a result of compartmentalization and means that the
vesicles are most likely not unilamellar.

Figure 3.3.5. 300 mM TmDTPA-2 200 nm LaPC+C vesicle CEST spectra.

Figure 3.3.6. 300 mM YDTPA-2 200 nm LaPC+C vesicle CEST spectra.
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The 300 mM TmDTPA-2 200 nm LaPC+C vesicles also did not produce any CEST
signal, aside from a general broadening of the direct water saturation (Figure 3.3.5). The
LaPC+C TmDTPA-2 sample was broader than the LaPC only TmDTPA-2 sample, which is
expected due to the fact that the water exchange rate in the cholesterol system should be
longer. Again, the 300 mM YDTPA-2 LaPC+C vesicles had narrow water saturation peaks
(Figure 3.3.6) similar to the LaPC only vesicle sample.
The spectra collected are difficult to assess due to the control sample spectra not
coming out like they should. The YDTPA-2 spectra (Figures 3.3.4 and 3.36) look as though
the experiment was not set up properly, with either the FID not collected fully or the O1P
value not being set properly. Given that both of the YDTPA-2 samples had noninterpretable
data, but both of the TmDTPA-2 samples were interpretable, the experimental set up being
the problem is not likely. The TmDTPA-2 samples had slight asymmetry associated with
them (Figure 3.3.7) when compared to the YDTPA-2 samples, but within a couple ppm of
O1P where the CEST signal from 300 mM TmDTPA-2 should not have been.
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Figure 3.3.7. CEST asymmetric analysis. Top left: YDTPA-2 200 nm LaPC. Top right: TmDTPA-2 200 nm
LaPC. Bottom left: YDTPA-2 200 nm LaPC+C. Bottom right: TmDTPA-2 200 nm LaPC+C.

In spite of the CEST data not looking promising, a simulation was run to calculate the
exchange rates in the system and the values suggested that the asymmetry in the recorded
CEST spectra did not correspond to CEST from shifted water in the interior compartment.
The LaPC vesicles have fast exchange since they are above the phase transition temperature
at room temperature. Adding cholesterol does not slow the exchange rate down enough to
have two compartments that are not well mixed. In order to further slow water exchange,
a sample of 200 nm DPPC vesicles was made with 300 mM TmDTPA-2 encapsulated in
them.
DPPC Vesicles
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The CEST spectra collected on the DPPC vesicles (Figure 3.3.8) looks similar to the
LaPC and LaPC+C CEST spectra (Figures 3.3.3, 3.3.4, 3.3.5, and 3.3.6), but instead of
resembling the TmDTPA-2 spectra, they look like a mixture between the TmDTPA-2
samples and the YDTPA-2 samples. There is broadening in the sample, and maybe some
asymmetry, but the baseline is not clean and hard to interpret.

Figure 3.3.8. 300 mM TmDTPA-2 200 nm DPPC vesicle CEST spectra.

3.4.

Conclusions
The LaPC vesicles studied have fast water exchange kinetics across the phospholipid

bilayer, which makes them difficult to study by T1 and CEST analysis. The collection
methods for both the T1 and CEST experiments need to be optimized for more studies.
Also of interest would be using a different lipid system, like DPPC instead of LaPC. LaPC
is above the phase transition temperature at room temperature while DPPC is above the
phase transition temperature at room temperature. The DPPC vesicles were difficult to
produce and were not pursued in these studies, but they should be, especially with the
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incorporation of cholesterol to help bring down the phase transition temperature to a more
workable temperature instead of 43°C.
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CHAPTER 4. MATERIALS AND METHODS
4.1.

Ln NB-DOTAM Project

Figure 4.1.1. Synthetic route to Ln-NB-DOTAM chelates.

General Remarks:
All solvents and reagents were purchased from commercial sources and used as
received unless otherwise stated. Both the S- and R- isomers of 2-bromo-N-(1phenylethyl)acetamide 1 were prepared according to previously described methods. HPLC
purification was undertaken on a Waters δ-Prep 150 HPLC system using a Phenomenex
Luna C-18(2) reversed-phase (50 × 250 mm) column. Elution was monitored by
absorption at 270 nm. All NMR spectra were recorded on a Bruker Advance IIa
spectrometer operating at 400.13 MHz (1H) and 100.61 MHz (13C) using a 5 mm broadband
probe with the temperature controlled using the installed variable-temperature controller
BVT3200 with BCU-05 chiller. Samples for two-dimensional COSY spectroscopy were
prepared in CD3OD (99.8 atom %). Two-dimensional COSY spectra were acquired using
4096 × 1024 points using 16 transients per FID at 263 K. Samples for CEST spectra were
prepared in dry CD3CN (99.8 atom %) and a known volume of H2O added. The
concentrations of each sample was determined by comparison of the intensity of the 19F
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NMR signal with that of a 1.0 M solution of Cu(OTf)2 placed in a concentric insert in the
NMR tube. CEST spectra were acquired at 275 K acquired by measuring the water signal
intensity as a function of presaturation offset, in 1 ppm increments. The duration of the
presaturation pulse was 10s with a B1 power of 148, 203, 279, 350 and 446 Hz.
(1R, 4R, 7R, 10R)- δ, δ′, δ′′, δ′′′-Tetramethyl-[2-(S)-(p-nitrobenzyl)-1,4,7,10tetraazacyclo dodecane ]-1,4,7,10-tetra (2-phenylethyl)acetamide dihydrochloride
salt (S-RRRR-2)
R-2-Bromo-N-(1-phenylethyl)acetamide 1 (497 mg, 2.05 mmol) S-2-(p-nitrobenzyl)
cyclen (150 mg, 0.488 mmol) and potassium carbonate (337 mg, 2.44 mmol) were added
to acetonitrile (50 mL). The resulting suspension was heated with stirring for 72 hours at
60 ˚C. Following addition of more bromoacetamide 1 (83 mg, 0.34 mmol) the reaction
was heated for a further 48 hours. After cooling to room temperature the solvents were
removed under reduced pressure and the residue divided between water (30 mL) and
dichloromethane (200 mL). After separation the aqueous phase was further extracted with
dichloromethane (2 × 50 mL), the organic phases were combined, dried (Na2SO4) and the
solvents removed under reduced pressure. The residue was taken up into a minimal amount
of acetonitrile (6 mL) and purified by RP-HPLC employing a mobile phase of water (0.37%
HCl) for 5 minutes followed by a linear gradient over 20 minutes to 60% MeCN and 20 %
water (0.37% HCl), after removal of the solvent by lyophilization the title compound was
obtained as a colorless solid (1.4 g, 67%).
RT = 29.02 min; 1H NMR (CH3CN, 400 MHz) δ 9.52 (2H, d, 3JH-H = 8 Hz, p-Ar), 8.04
(2H, d, 3JH-H = 8 Hz, p-Ar), 8.49 (2H, br, CONH), 8.38 (2H, br, CONH), 7.4-6.9 (20H, m,
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Ar), 4.91 (4H, m, CHCH3), 4.78 (1H, dd (aa′ pattern), 3JH-H = 7 Hz, CH2Ar), 4.76 (1H, dd
(aa′ pattern), 3JH-H = 7 Hz, CH2Ar), 3.9-2.5 (23H, m br, NCH2 ring and NCH2CO), 1.36
(12H, m, CH3); 13C NMR (CH3CN, 100 MHz) δ 20.9 (CH3), 21.7 (CH3), 22.0 (CH3), 22.2
(CH3), 32.6 (CH2Ar), 48.6, 48.8, 48.9, 49.0, 49.3, 49.5, 49.69, 50.2, 51.1, 51.6, 52.8, 53.3,
53.4, 54.7, 56.5, 56.6, 123.2, 123.5, 125.7, 125.9, 126.3 - 126.9 (several, overlapping),
128.0 - 128.4 (several, overlapping), 130.2, 143.3, 143.6, 143.9, 144.6, 144.9, 146.4, 146.7,
161.8 (C=O), 162.7 (C=O), 167.9 (C=O), 172.0 (C=O); m/z (ESMS EI+): 952 ( 100 %, [M
+ H] +).
(1S, 4S, 7S, 10S)- δ, δ′, δ′′, δ′′′-Tetramethyl-[2-(S)-(p-nitrobenzyl)-1,4,7,10tetraazacyclo dodecane ]-1,4,7,10-tetra (2-phenylethyl)acetamide dihydrochloride
salt (S-SSSS-2)
The title compound was prepared in an identical manner using S-2-bromo-N-(1phenylethyl)acetamide 1. After prep RP-HPLC the title compound was obtained as a
colorless solid (0.8 g, 52 %).
RT = 29.84 min; 1H NMR (CD3CN, 400 MHz) 7.97 (2H, d, 3JH-H = 8 Hz, p-Ar), 7.44
(20H, m, Ar), 7.31 (2H, d, 3JH-H = 8 Hz, p-Ar), 7.02 (4H, br, CONH), 4.91 (4H, m, CHCH3),
4.76 (2H, s br, CH2Ar), 2.7-2.1 (23H, m br, NCH2 ring and NCH2CO), 1.31 (12H, m, CH3);
C NMR (CH3CN, 100 MHz) δ 21.2 (CH3), 21.8 (CH3), 22.1 (CH3), 22.3 (CH3), 36.4

13

(CH2Ar), 46.9, 47.8, 48.9, 49.0, 49.4, 49.6, 49.7, 49.8, 51.5, 51.8, 53.0, 53.3, 53.4, 53.7,
56.1, 57.0, 122.8, 123.1, 125.5 - 126.9 (several, overlapping), 128.4 - 128.7 (several,
overlapping), 123.8, 131.4, 142.7, 143.0, 143.8, 144.9, 145.2, 146.7, 147.7, 162.0 (C=O),
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162.5 (C=O), 168.5 (C=O), 171.4 (C=O); m/z (ESMS EI+): 952 ( 100 %, [M+H] +), 974
(46 %, [M+Na] +).
General method for the preparation of Ln2(OTf)3 chelates.
The corresponding lanthanide triflate (73 µmol) was dissolved in (4 mL) and added to
a solution of the ligand either S-RRRR- or S-SSSS-2 (50 mg, 49 µmol) in 50/50
acetonitrile/water (4 mL). The resulting solution was heated with stirring for 24 hours at
60 ˚C. The solution was filtered through a 0.45 µm syringe filter and introduced directly
to the HPLC for purification. Purification was undertaken using a mobile phase of water
(0.1% TFA) for 5 minutes followed by a linear gradient to 10% MeCN and 90 % water
(0.1% TFA) over 15 minutes. Each chelate was collected from a single major peak in the
chromatogram and removal of the solvents by lyophilization afforded the chelate as the
corresponding triflate salt as a colorless solid.
Mass Spectrometry
S-RRRR-Ce2(OTf)3
HRMS (ESI-TOF) m/z: [M]3+ Calcd for C55H69N9CeO6 363.8142; Found 363.8135; [M +
OTf]2+ Calcd for C56H69F3N9CeO9S 620.1973; Found 622.1970; the appropriate Ce3+
isotope pattern was observed.
S-RRRR-Pr2(OTf)3
HRMS (ESI-TOF) m/z: [M]3+ Calcd for C55H69N9PrO6 364.1477; Found 364.1472; [M +
OTf]2+ Calcd for C56H69F3N9PrO9S 620.6976; Found 620.6977; the appropriate Pr3+
isotope pattern was observed.
S-RRRR-Nd2(OTf)3
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HRMS (ESI-TOF) m/z: [M]3+ Calcd for C55H69N9NdO6 364.4816; Found 364.4806; [M +
OTf]2+ Calcd for C56H69F3N9NdO9S 622.1996; Found 622.1986; the appropriate Nd3+
isotope pattern was observed.
S-RRRR-Sm2(OTf)3
HRMS (ESI-TOF) m/z: Calcd for C55H69N9SmO6 367.6189; Found 367.6175; [M + OTf]2+
Calcd for C56H69F3N9SmO9S 626.2044; Found 626.2028; the appropriate Sm3+ isotope
pattern was observed.
S-RRRR-Eu2(OTf)3
HRMS (ESI-TOF) m/z: [M]3+ Calcd for C55H69N9EuO6 368.1528; Found 368.1538; [M +
OTf]2+ Calcd for C56H69F3N9EuO9S 626.7052; Found 622.7074; the appropriate Ce3+
isotope pattern was observed.
S-RRRR-Tb2(OTf)3
HRMS (ESI-TOF) m/z: [M]3+ Calcd for C55H69N9TbO6 370.1541; Found 370.1533; [M +
OTf]2+ Calcd for C56H69F3N9TbO9S 629.7072; Found 629.7063; the appropriate Tb3+
isotope pattern was observed.
S-RRRR-Dy2(OTf)3
HRMS (ESI-TOF) m/z: [M]3+ Calcd for C55H69N9DyO6 371.8221; Found 371.8213; [M +
OTf]2+ Calcd for C56H69F3N9DyO9S 632.2092; Found 632.2083; the appropriate Dy3+
isotope pattern was observed.
S-RRRR-Er2(OTf)3
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HRMS (ESI-TOF) m/z: [M]3+ Calcd for C55H69N9ErO6 372.4891; Found 372.4881; [M +
OTf]2+ Calcd for C56H69F3N9ErO9S 634.2108; Found 634.2098; the appropriate Er3+
isotope pattern was observed.
S-RRRR-Yb2(OTf)3
HRMS (ESI-TOF) m/z: [M]3+ Calcd for C55H69N9YbO6 375.1586; Found 375.1589; [M +
OTf]2+ Calcd for C56H69F3N9YbO9S 637.2140; Found 637.2162; the appropriate Yb3+
isotope pattern was observed.
S-SSSS-Ce2(OTf)3
HRMS (ESI-TOF) m/z: [M]3+ Calcd for C55H69N9CeO6 363.8142; Found 363.8133; [M +
OTf]2+ Calcd for C56H69F3N9CeO9S 620.1973; Found 620.1967; the appropriate Ce3+
isotope pattern was observed.
S-SSSS-Pr2(OTf)3
HRMS (ESI-TOF) m/z: [M]3+ Calcd for C55H69N9PrO6 364.1477; Found 364.1473; [M +
OTf]2+ Calcd for C56H69F3N9PrO9S 620.6976; Found 620.6976; the appropriate Pr3+
isotope pattern was observed.
S-SSSS-Eu2(OTf)3
HRMS (ESI-TOF) m/z: [M]3+ Calcd for C55H69N9EuO6 368.1528; Found 368.1537; [M +
OTf]2+ Calcd for C56H69F3N9EuO9S 626.7052; Found 626.7072; the appropriate Eu3+
isotope pattern was observed.
S-SSSS-Tb2(OTf)3
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HRMS (ESI-TOF) m/z: [M]3+ Calcd for C55H69N9TbO6 370.1541; Found 370.1532; [M +
OTf]2+ Calcd for C56H69F3N9TbO9S 629.7072; Found 629.7062; the appropriate Tb3+
isotope pattern was observed.
S-SSSS-Dy2(OTf)3
HRMS (ESI-TOF) m/z: [M]3+ Calcd for C55H69N9DyO6 371.8221; Found 371.8208; [M +
OTf]2+ Calcd for C56H69F3N9DyO9S 632.2092; Found 632.2075; the appropriate Dy3+
isotope pattern was observed.
S-SSSS-Ho2(OTf)3
HRMS (ESI-TOF) m/z: [M]3+ Calcd for C55H69N9HoO6 372.1558; Found 372.1547; [M +
OTf]2+ Calcd for C56H69F3N9HoO9S 632.7097; Found 632.7086; the appropriate Ho3+
isotope pattern was observed.
S-SSSS-Er2(OTf)3
HRMS (ESI-TOF) m/z: [M]3+ Calcd for C55H69N9ErO6 372.4891; Found 372.4886; [M +
OTf]2+ Calcd for C56H69F3N9ErO9S 634.2108; Found 634.2001; the appropriate Er3+
isotope pattern was observed.
S-SSSS-Yb2(OTf)3
HRMS (ESI-TOF) m/z: [M]3+ Calcd for C55H69N9YbO6 375.1586; Found 375.1599; [M +
OTf]2+ Calcd for C56H69F3N9YbO9S 637.2140; Found 622.2162; the appropriate Yb3+
isotope pattern was observed.
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Vesicle Project

Vesicle Synthesis
0.05 g L-α-phosphatidylcholine was weighed into a round bottom flask. Chloroform
was added to dissolve the lipid and then removed under vacuum. The lipid was then
suspended in the desired buffer system, agitated through swirling, stirring, and rotating
until the thin film of lipid was removed from the wall of the round bottom flask. The lipid
was then extruded through the Lipex 10 mL water jacketed extruder (TRANSFERRA
Nanosciences Inc) through polycarbonate membranes with pores of the desired sizes a total
of 10 times. The polycarbonate membranes were removed and placed at any point in the
extrusion process if the synthesis was difficult and lipid was falling out of solution and
blocking the passage of the vesicle mixture through the filter. After 10 passes through the
desired filter size, the samples were analyzed by DLS for sizing.
If the chelate being studied was inside the vesicles, it was in the buffer solution used to
make the vesicles after solvent was removed under vacuum. Once the vesicles were sized,
1 mL of the sample was placed into a Float-a-lyzer dialysis membrane and was dialyzed
against bath buffer to remove the excess chelate. If the chelate being studied was outside
the vesicles, it was added to a small sample of prepared vesicles (1 mL).
Collecting the Data
The T1 inversion recovery curve experiment requires picking τ values that allow some
of the sample signal to relax back to the z-axis and some of it to not relax back to the zaxis. Picking τ values appropriate for the sample in question is generally done on a “Is it
expected to have a short or long T1?” basis. However, in the case of vesicles with
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GdDTPA-2, two T1 values are present and may require equal consideration while picking τ
values for the experiment. As an example, the 5 mM GdDPTA-2 sample was run with the
5 mM GdDTPA-2 VD list, which has shorter τ values (5.2 ms to 600 ms) than all of the
other sample VD lists, and the 1 mM GdDTPA-2 sample was run with the 1 mM GdDTPA2

VD list, which has longer τ values (26 ms to 3 s) than the other sample VD lists. In the

case of the 1 mM GdDTPA-2 vesicle sample, the amount of signal belonging to
encapsulated water (the longer T1 value) wouldn’t really be cut down that much due to the
1 mM GdDTPA-2 using longer τ values, where the amount of signal belonging to
encapsulated water would be cut off quite a bit since the longest it waits for is 600 ms. By
using the concentration dependent VD lists, the samples were essentially being T1weighted. In order to see if this was occurring, a concentration independent VD list was
used, with τ values from 5 ms to 15 s. This data collection method was employed for several
different samples after the idea was brough up, but it wasn’t until later in the experiments,
meaning there is no normal system to compare to. Therefore, the concentration independent
VD list used is compared to the same sample run with the concentration dependent VD list.
Processing the Data
Some data, when processed using the “original (O) method” of analysis, did not
produce recovery curves that could be considered useful. In particular, 0 mM GdDTPA-2
samples (samples of just buffer and vesicles) and 1 mM GdDTPA-2 samples provided
difficult recovery curves. After attempting to make sure the relaxation delays and VD lists
were appropriate, Dr. Peyton was kind enough to help with the data analysis portion done
on the spectrometer computer. Dr. Peyton first phased and then baseline corrected the last
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spectrum of each experimental run and applied the analysis to all of the spectra collected
in the experiment. The T1 analysis was followed, but instead of an integration assignment
for the program to follow, he manually picked the peak to follow. After his changes to the
method, difficult samples that produced messy or incomplete recovery curves suddenly had
near perfect recovery curves. Since the analysis method was suggested late in the data
collection process, all of the previously analyzed data using the original method were reanalyzed using the “professional (P) method”. The analysis using excel was the same no
matter the type of analysis that was performed on the spectrometer computer.
Monoexponential Fitting
The intensity values from the text file were normalized using the following equation:
B"+"*CD"+*+()EF GCD*#).*+(EF HE(E I")+( =

J K
J ∞

Where I(τ) is the intensity at that τ value and I(∞) is the intensity at an assumed ∞ τ
value where the spins have relaxed completely. For the 600 MHz data, the I(∞) value was
taken to be the highest intensity point in the experimental data, which was at the end of the
experiment run with the longest τ value.
The recovery curve from the experimental intensity values was compared to a
calculated curve which was produced from a population size, M0, a relaxivity value, R1,
and the time point, τ, and using the following equation:
B"+"*CD"+*+()EF MEF,%FE(*N HE(E I")+( = BO

2BO ∗ *

RS∗TU

The values of M0 and R1 were allowed to float in the calculation so that they would be
representative of the species being measured.
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The two sets (the experimental and calculated) were analyzed using the following
equation in excel:
= VWX Y

ZB[B\2 #E+]* "^ *CD*#).*+(EF _EF%*', #E+]* "^ ,EF,%FE(*N _EF%*'
`
ZB V #E+]* "^ *CD*#).*+(EF _EF%*'

The resulting value was minimized using the data solver function in excel, with the
values of M0 and R1 being able to change to make the best match of the calculated values
to the experimental values. Once the fit between the two sets of data was minimized, the
R1 and M0 values were used to assess the T1 of the sample and the population size,
respectively.
Biexponential Fitting
The intensity values from the text file were manipulated using the following
equation from a paper where biexponential fitting was performed:
a)*CD"+*+()EF GCD*#).*+(EF HE(E I")+( =

J ∞
J K
2∗J ∞

Where I(∞) is the intensity at an assumed ∞ τ value where the spins have relaxed
completely (the highest intensity point in the experimental data at the end of the experiment
run with the longest τ value ) and I(τ) is the intensity at that τ value.
The experimental intensity values were compared to a calculated curve which was
produced from a small population size, MS, and a small population relaxivity value, RS1, a
large population size, ML, and a large population relaxivity value, RL1, and the time point,
τ, and using the following equation:
a)*CD"+*+()EF MEF,%FE(*N HE(E I")+( = Bb ∗ *

RS∗TcU

+ Be ∗ *

RS∗TfU
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The values of MS, ML, RS1, and RL1 were allowed to float in the calculation so that they
would be representative of the species being measured.
The two sets (the experimental and calculated) were analyzed using the following
equation in excel:
= VWX Y

ZB[B\2 #E+]* "^ *CD*#).*+(EF _EF%*', #E+]* "^ ,EF,%FE(*N _EF%*'
`
ZB V #E+]* "^ *CD*#).*+(EF _EF%*'

The resulting value was minimized using the data solver function in excel, with the
values of MS, ML, RS1, and RL1 being able to change to make the best match of the
calculated values to the experimental values. Once the fit between the two sets of data was
minimized, the MS, ML, RS1, and RL1 values were used to assess the T1 values of the two
species in the sample and the population sizes of each.
CEST Experiments
CEST spectra were acquired at 25°C acquired by measuring the water signal intensity
as a function of presaturation offset, in 1 ppm increments. The duration of the presaturation
pulse was 10s with a B1 power of 148, 203, 279, 350 and 446 Hz.
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